ONTOLOGY REPORT - ANNOTATIONS
| Term: | tertiary amine |
|
| Accession: | CHEBI:32876
|
browse the term
|
| Definition: | A compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups. |
| Synonyms: | exact_synonym: | tertiary amines |
| | related_synonym: | NR3; R3N; [*]N([*])[*]; tertiaeres Amin |
| | alt_id: | CHEBI:26879; CHEBI:9458 |
| | xref: | KEGG COMPOUND:C02196 "KEGG COMPOUND" |
|
|
(-)-lobeline
|
| G |
Chrna4 |
cholinergic receptor, nicotinic, alpha 4 (neuronal) |
|
multiple interactions |
ISO |
3 |
170,171,214 |
170,185,998 |
RGD:6480464 |
CTD |
| G |
Chrna4 |
cholinergic receptor, nicotinic, alpha 4 (neuronal) |
|
multiple interactions |
ISO |
3 |
170,171,214 |
170,185,998 |
RGD:6480464 |
CTD |
| G |
Chrnb2 |
cholinergic receptor, nicotinic, beta 2 (neuronal) |
|
multiple interactions |
ISO |
2 |
181,961,373 |
181,969,581 |
RGD:6480464 |
CTD |
| G |
Chrnb2 |
cholinergic receptor, nicotinic, beta 2 (neuronal) |
|
multiple interactions |
ISO |
2 |
181,961,373 |
181,969,581 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
multiple interactions |
ISO |
10 |
89,821,078 |
89,872,970 |
RGD:6480464 |
CTD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
multiple interactions |
ISO |
10 |
89,821,078 |
89,872,970 |
RGD:6480464 |
CTD |
(-)-selegiline
|
| G |
Aifm1 |
apoptosis-inducing factor, mitochondrion-associated 1 |
|
multiple interactions |
ISO |
X |
134,868,878 |
134,908,166 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
multiple interactions |
EXP |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
increases phosphorylation |
EXP |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cycs |
cytochrome c, somatic |
|
multiple interactions |
ISO |
4 |
78,825,878 |
78,827,978 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
affects metabolic processing |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
|
multiple interactions |
EXP |
4 |
161,282,215 |
161,286,090 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
increases expression |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
affects binding |
ISO |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
multiple interactions |
ISO |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
multiple interactions |
ISO |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
decreases activity |
EXP |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
multiple interactions |
EXP |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
decreases activity |
EXP |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
decreases activity |
EXP |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
decreases activity |
EXP |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
decreases activity |
EXP |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases phosphorylation |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases phosphorylation |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases phosphorylation |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases phosphorylation |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mt1a |
metallothionein 1a |
|
multiple interactions |
ISO |
19 |
11,261,631 |
11,262,647 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
multiple interactions |
ISO |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
increases phosphorylation |
ISO |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
multiple interactions |
EXP |
3 |
58,366,693 |
58,394,116 |
RGD:6480464 |
CTD |
| G |
Nfe2l2 |
nuclear factor, erythroid derived 2, like 2 |
|
increases localization |
EXP |
3 |
58,366,693 |
58,394,116 |
RGD:6480464 |
CTD |
| G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
|
multiple interactions |
EXP |
19 |
37,251,147 |
37,266,040 |
RGD:6480464 |
CTD |
| G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
|
increases activity |
EXP |
19 |
37,251,147 |
37,266,040 |
RGD:6480464 |
CTD |
| G |
Park2 |
parkinson protein 2, E3 ubiquitin protein ligase |
|
multiple interactions |
ISO |
1 |
43,151,265 |
44,374,470 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Siah1a |
seven in absentia 1A |
|
multiple interactions |
EXP |
19 |
21,717,141 |
21,740,751 |
RGD:6480464 |
CTD |
| G |
Snca |
synuclein, alpha (non A4 component of amyloid precursor) |
|
multiple interactions |
ISO |
4 |
89,613,731 |
89,722,807 |
RGD:6480464 |
CTD |
| G |
Snca |
synuclein, alpha (non A4 component of amyloid precursor) |
|
multiple interactions |
ISO |
4 |
89,613,731 |
89,722,807 |
RGD:6480464 |
CTD |
| G |
Th |
tyrosine hydroxylase |
|
decreases expression |
EXP |
1 |
203,164,253 |
203,171,506 |
RGD:6480464 |
CTD |
| G |
Th |
tyrosine hydroxylase |
|
multiple interactions |
EXP |
1 |
203,164,253 |
203,171,506 |
RGD:6480464 |
CTD |
| G |
Txn1 |
thioredoxin 1 |
|
multiple interactions |
ISO |
5 |
75,921,365 |
75,933,595 |
RGD:6480464 |
CTD |
| G |
Txn1 |
thioredoxin 1 |
|
affects response to substance |
ISO |
5 |
75,921,365 |
75,933,595 |
RGD:6480464 |
CTD |
| G |
Txn1 |
thioredoxin 1 |
|
increases expression |
ISO |
5 |
75,921,365 |
75,933,595 |
RGD:6480464 |
CTD |
| G |
Txn1 |
thioredoxin 1 |
|
affects response to substance |
ISO |
5 |
75,921,365 |
75,933,595 |
RGD:6480464 |
CTD |
| G |
Txn1 |
thioredoxin 1 |
|
increases expression |
ISO |
5 |
75,921,365 |
75,933,595 |
RGD:6480464 |
CTD |
(Z)-chlorprothixene
|
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
multiple interactions |
ISO |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
increases secretion |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
almotriptan
|
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases metabolic processing |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
decreases methylation |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases hydroxylation |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
decreases methylation |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
decreases methylation |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
decreases methylation |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
increases hydroxylation |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
decreases methylation |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
increases hydroxylation |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases hydroxylation |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
decreases methylation |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Fmo3 |
flavin containing monooxygenase 3 |
|
increases oxidation |
ISO |
13 |
78,659,513 |
78,678,524 |
RGD:6480464 |
CTD |
| G |
Htr1b |
5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled |
|
multiple interactions |
ISO |
8 |
86,700,088 |
86,701,248 |
RGD:6480464 |
CTD |
| G |
Maoa |
monoamine oxidase A |
|
increases metabolic processing |
ISO |
X |
17,678,960 |
17,745,908 |
RGD:6480464 |
CTD |
alverine
|
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
affects binding |
EXP |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
aminophenazone
|
| G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
|
decreases activity |
ISO |
3 |
15,343,832 |
15,365,412 |
RGD:6480464 |
CTD |
amitriptyline
|
| G |
Aadat |
aminoadipate aminotransferase |
|
affects expression |
EXP |
16 |
32,845,006 |
32,885,600 |
RGD:6480464 |
CTD |
| G |
Abat |
4-aminobutyrate aminotransferase |
|
decreases expression |
EXP |
10 |
7,040,725 |
7,137,154 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
affects expression |
EXP |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcd2 |
ATP-binding cassette, subfamily D (ALD), member 2 |
|
decreases expression |
EXP |
7 |
129,542,758 |
129,591,363 |
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
|
affects expression |
EXP |
1 |
223,731,675 |
223,773,285 |
RGD:6480464 |
CTD |
| G |
Ankrd1 |
ankyrin repeat domain 1 |
|
increases expression |
EXP |
1 |
240,316,123 |
240,324,804 |
RGD:6480464 |
CTD |
| G |
Ano3 |
anoctamin 3 |
|
decreases expression |
EXP |
3 |
96,123,925 |
96,237,157 |
RGD:6480464 |
CTD |
| G |
Ap1s1 |
adaptor-related protein complex 1, sigma 1 subunit |
|
decreases expression |
ISO |
12 |
20,907,855 |
20,918,301 |
RGD:6480464 |
CTD |
| G |
Ap1s1 |
adaptor-related protein complex 1, sigma 1 subunit |
|
decreases expression |
ISO |
12 |
20,907,855 |
20,918,301 |
RGD:6480464 |
CTD |
| G |
Apoa4 |
apolipoprotein A-IV |
|
affects expression |
EXP |
8 |
49,233,142 |
49,233,431 |
RGD:6480464 |
CTD |
| G |
Arg1 |
arginase, liver |
|
increases expression |
EXP |
1 |
20,998,894 |
21,011,275 |
RGD:6480464 |
CTD |
| G |
Asah1 |
N-acylsphingosine amidohydrolase (acid ceramidase) 1 |
|
increases expression |
ISO |
16 |
54,279,253 |
54,311,084 |
RGD:6480464 |
CTD |
| G |
Asah1 |
N-acylsphingosine amidohydrolase (acid ceramidase) 1 |
|
increases expression |
ISO |
16 |
54,279,253 |
54,311,084 |
RGD:6480464 |
CTD |
| G |
Asah1 |
N-acylsphingosine amidohydrolase (acid ceramidase) 1 |
|
increases expression |
ISO |
16 |
54,279,253 |
54,311,084 |
RGD:6480464 |
CTD |
| G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
|
increases expression |
ISO |
4 |
32,758,866 |
32,776,220 |
RGD:6480464 |
CTD |
| G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
|
increases expression |
ISO |
4 |
32,758,866 |
32,776,220 |
RGD:6480464 |
CTD |
| G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
|
increases expression |
ISO |
4 |
32,758,866 |
32,776,220 |
RGD:6480464 |
CTD |
| G |
Atf3 |
activating transcription factor 3 |
|
increases expression |
EXP |
13 |
107,191,622 |
107,223,850 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
multiple interactions |
EXP |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bhmt |
betaine-homocysteine S-methyltransferase |
|
affects expression |
EXP |
2 |
23,923,651 |
23,943,320 |
RGD:6480464 |
CTD |
| G |
C1qa |
complement component 1, q subcomponent, A chain |
|
increases expression |
EXP |
5 |
155,662,333 |
155,665,180 |
RGD:6480464 |
CTD |
| G |
C1qc |
complement component 1, q subcomponent, C chain |
|
increases expression |
EXP |
5 |
155,656,104 |
155,659,430 |
RGD:6480464 |
CTD |
| G |
Cacna2d1 |
calcium channel, voltage-dependent, alpha2/delta subunit 1 |
|
increases expression |
EXP |
4 |
15,139,881 |
15,566,740 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases expression |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casr |
calcium-sensing receptor |
|
decreases expression |
EXP |
11 |
66,084,169 |
66,153,292 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
decreases expression |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cd74 |
Cd74 molecule, major histocompatibility complex, class II invariant chain |
|
increases expression |
EXP |
18 |
56,756,511 |
56,765,711 |
RGD:6480464 |
CTD |
| G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) |
|
affects expression |
EXP |
5 |
131,012,524 |
131,017,679 |
RGD:6480464 |
CTD |
| G |
Ces2h |
carboxylesterase 2H |
|
affects expression |
EXP |
19 |
34,910,981 |
34,925,547 |
RGD:6480464 |
CTD |
| G |
Chat |
choline O-acetyltransferase |
|
increases expression |
EXP |
16 |
7,913,026 |
7,965,985 |
RGD:6480464 |
CTD |
| G |
Chrna3 |
cholinergic receptor, nicotinic, alpha 3 (neuronal) |
|
decreases expression |
EXP |
8 |
58,570,223 |
58,583,594 |
RGD:6480464 |
CTD |
| G |
Chrnb2 |
cholinergic receptor, nicotinic, beta 2 (neuronal) |
|
decreases expression |
EXP |
2 |
181,961,373 |
181,969,581 |
RGD:6480464 |
CTD |
| G |
Cmtm6 |
CKLF-like MARVEL transmembrane domain containing 6 |
|
affects expression |
EXP |
8 |
119,149,810 |
119,165,515 |
RGD:6480464 |
CTD |
| G |
Cpne4 |
copine IV |
|
decreases expression |
EXP |
8 |
109,627,862 |
110,112,935 |
RGD:6480464 |
CTD |
| G |
Cpped1 |
calcineurin-like phosphoesterase domain containing 1 |
|
affects expression |
EXP |
10 |
3,577,406 |
3,698,276 |
RGD:6480464 |
CTD |
| G |
Crem |
cAMP responsive element modulator |
|
affects expression |
EXP |
17 |
62,770,633 |
62,837,670 |
RGD:6480464 |
CTD |
| G |
Csrp3 |
cysteine and glycine-rich protein 3 (cardiac LIM protein) |
|
increases expression |
EXP |
1 |
98,601,681 |
98,611,747 |
RGD:6480464 |
CTD |
| G |
Cst12 |
cystatin 12 |
|
decreases expression |
EXP |
3 |
137,548,053 |
137,551,913 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
increases metabolic processing |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp2a1 |
cytochrome P450, family 2, subfamily a, polypeptide 1 |
|
affects expression |
EXP |
1 |
82,006,828 |
82,020,282 |
RGD:6480464 |
CTD |
| G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
|
increases expression |
EXP |
1 |
81,266,828 |
81,290,471 |
RGD:6480464 |
CTD |
| G |
Cyp2b15 |
cytochrome P450, family 2, subfamily b, polypeptide 15 |
|
affects expression |
EXP |
1 |
81,839,930 |
81,852,366 |
RGD:6480464 |
CTD |
| G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
|
increases expression |
EXP |
1 |
81,345,425 |
81,359,415 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
decreases activity |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
increases metabolic processing |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
increases metabolic processing |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
increases metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
decreases activity |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
increases metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a23/3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23/polypeptide 1 |
|
increases expression |
EXP |
12 |
9,567,120 |
9,595,974 |
RGD:6480464 |
CTD |
| G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
|
increases metabolic processing |
ISO |
12 |
17,164,384 |
17,204,589 |
RGD:6480464 |
CTD |
| G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
|
affects expression |
EXP |
16 |
18,183,761 |
18,225,158 |
RGD:6480464 |
CTD |
| G |
Cyp4f4 |
cytochrome P450, family 4, subfamily f, polypeptide 4 |
|
affects expression |
EXP |
7 |
13,293,080 |
13,309,416 |
RGD:6480464 |
CTD |
| G |
Dcaf8 |
DDB1 and CUL4 associated factor 8 |
|
affects expression |
EXP |
13 |
88,029,285 |
88,186,506 |
RGD:6480464 |
CTD |
| G |
Dnmt1 |
DNA (cytosine-5-)-methyltransferase 1 |
|
decreases activity |
EXP |
8 |
19,926,995 |
19,973,256 |
RGD:6480464 |
CTD |
| G |
Drd1 |
dopamine receptor D1 |
|
increases expression |
EXP |
17 |
16,655,926 |
16,658,161 |
RGD:6480464 |
CTD |
| G |
Drd3 |
dopamine receptor D3 |
|
increases expression |
EXP |
11 |
58,446,901 |
58,520,589 |
RGD:6480464 |
CTD |
| G |
Ecel1 |
endothelin converting enzyme-like 1 |
|
increases expression |
EXP |
9 |
85,933,894 |
85,946,083 |
RGD:6480464 |
CTD |
| G |
Eif4b |
eukaryotic translation initiation factor 4B |
|
affects expression |
EXP |
7 |
140,814,663 |
140,836,485 |
RGD:6480464 |
CTD |
| G |
Ephx1 |
epoxide hydrolase 1, microsomal (xenobiotic) |
|
affects expression |
EXP |
13 |
96,722,973 |
96,752,940 |
RGD:6480464 |
CTD |
| G |
Erp29 |
endoplasmic reticulum protein 29 |
|
affects expression |
EXP |
12 |
36,225,110 |
36,231,363 |
RGD:6480464 |
CTD |
| G |
Fabp1 |
fatty acid binding protein 1, liver |
|
increases expression |
ISO |
4 |
104,412,200 |
104,415,981 |
RGD:6480464 |
CTD |
| G |
Fabp1 |
fatty acid binding protein 1, liver |
|
increases expression |
ISO |
4 |
104,412,200 |
104,415,981 |
RGD:6480464 |
CTD |
| G |
Fabp1 |
fatty acid binding protein 1, liver |
|
increases expression |
ISO |
4 |
104,412,200 |
104,415,981 |
RGD:6480464 |
CTD |
| G |
Flrt3 |
fibronectin leucine rich transmembrane protein 3 |
|
increases expression |
EXP |
3 |
128,922,726 |
128,934,866 |
RGD:6480464 |
CTD |
| G |
Gabra1 |
gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
|
increases expression |
EXP |
10 |
27,258,813 |
27,313,725 |
RGD:6480464 |
CTD |
| G |
Gabra1 |
gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
|
decreases expression |
EXP |
10 |
27,258,813 |
27,313,725 |
RGD:6480464 |
CTD |
| G |
Gabra2 |
gamma-aminobutyric acid (GABA) A receptor, alpha 2 |
|
increases expression |
EXP |
14 |
39,568,677 |
39,705,897 |
RGD:6480464 |
CTD |
| G |
Gabra4 |
gamma-aminobutyric acid (GABA) A receptor, alpha 4 |
|
increases expression |
EXP |
14 |
39,047,461 |
39,122,531 |
RGD:6480464 |
CTD |
| G |
Gabrb3 |
gamma-aminobutyric acid (GABA) A receptor, beta 3 |
|
increases expression |
EXP |
1 |
109,047,399 |
109,277,756 |
RGD:6480464 |
CTD |
| G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
|
increases expression |
EXP |
4 |
96,649,941 |
96,652,243 |
RGD:6480464 |
CTD |
| G |
Gal |
galanin/GMAP prepropeptide |
|
increases expression |
EXP |
1 |
205,936,352 |
205,941,215 |
RGD:6480464 |
CTD |
| G |
Gckr |
glucokinase (hexokinase 4) regulator |
|
affects expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
|
increases expression |
ISO |
1 |
185,941,893 |
185,984,348 |
RGD:6480464 |
CTD |
| G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
|
increases expression |
ISO |
1 |
185,941,893 |
185,984,348 |
RGD:6480464 |
CTD |
| G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
|
increases expression |
ISO |
1 |
185,941,893 |
185,984,348 |
RGD:6480464 |
CTD |
| G |
Gls2 |
glutaminase 2 (liver, mitochondrial) |
|
affects expression |
EXP |
7 |
1,484,397 |
1,495,283 |
RGD:6480464 |
CTD |
| G |
Got2 |
glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate aminotransferase 2) |
|
affects expression |
EXP |
19 |
9,629,687 |
9,655,336 |
RGD:6480464 |
CTD |
| G |
Grb14 |
growth factor receptor bound protein 14 |
|
affects expression |
EXP |
3 |
46,832,380 |
46,952,670 |
RGD:6480464 |
CTD |
| G |
Grik1 |
glutamate receptor, ionotropic, kainate 1 |
|
decreases expression |
EXP |
11 |
27,703,874 |
28,106,450 |
RGD:6480464 |
CTD |
| G |
Gstp1 |
glutathione S-transferase pi 1 |
|
decreases activity |
ISO |
1 |
206,627,398 |
206,629,866 |
RGD:6480464 |
CTD |
| G |
H2afy |
H2A histone family, member Y |
|
affects expression |
EXP |
17 |
14,457,307 |
14,520,963 |
RGD:6480464 |
CTD |
| G |
Hal |
histidine ammonia lyase |
|
affects expression |
EXP |
7 |
30,520,913 |
30,551,145 |
RGD:6480464 |
CTD |
| G |
Hmgb2 |
high mobility group box 2 |
|
affects expression |
EXP |
16 |
36,131,304 |
36,133,878 |
RGD:6480464 |
CTD |
| G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) |
|
increases expression |
ISO |
2 |
51,737,090 |
51,754,583 |
RGD:6480464 |
CTD |
| G |
Hoxd1 |
homeo box D1 |
|
decreases expression |
EXP |
3 |
57,377,839 |
57,379,978 |
RGD:6480464 |
CTD |
| G |
Hpn |
hepsin |
|
increases expression |
ISO |
1 |
86,145,615 |
86,161,091 |
RGD:6480464 |
CTD |
| G |
Hpn |
hepsin |
|
increases expression |
ISO |
1 |
86,145,615 |
86,161,091 |
RGD:6480464 |
CTD |
| G |
Hpn |
hepsin |
|
increases expression |
ISO |
1 |
86,145,615 |
86,161,091 |
RGD:6480464 |
CTD |
| G |
Hpse |
heparanase |
|
decreases expression |
EXP |
14 |
10,144,322 |
10,185,115 |
RGD:6480464 |
CTD |
| G |
Hs3st2 |
heparan sulfate (glucosamine) 3-O-sulfotransferase 2 |
|
decreases expression |
EXP |
1 |
180,202,791 |
180,324,718 |
RGD:6480464 |
CTD |
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
increases expression |
EXP |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Htr1d |
5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled |
|
decreases expression |
EXP |
5 |
155,188,669 |
155,189,793 |
RGD:6480464 |
CTD |
| G |
Htr2c |
5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled |
|
affects binding |
ISO |
X |
31,012,921 |
31,244,127 |
RGD:6480464 |
CTD |
| G |
Il33 |
interleukin 33 |
|
affects expression |
EXP |
1 |
233,670,801 |
233,685,798 |
RGD:6480464 |
CTD |
| G |
Inadl |
InaD-like (Drosophila) |
|
decreases expression |
EXP |
5 |
118,806,744 |
119,131,114 |
RGD:6480464 |
CTD |
| G |
Inhbe |
inhibin beta E |
|
increases expression |
ISO |
7 |
67,308,713 |
67,310,138 |
RGD:6480464 |
CTD |
| G |
Inhbe |
inhibin beta E |
|
increases expression |
ISO |
7 |
67,308,713 |
67,310,138 |
RGD:6480464 |
CTD |
| G |
Inhbe |
inhibin beta E |
|
increases expression |
ISO |
7 |
67,308,713 |
67,310,138 |
RGD:6480464 |
CTD |
| G |
Itgb6 |
integrin, beta 6 |
|
decreases expression |
EXP |
3 |
42,286,140 |
42,360,793 |
RGD:6480464 |
CTD |
| G |
Kcna4 |
potassium voltage-gated channel, shaker-related subfamily, member 4 |
|
decreases expression |
EXP |
3 |
92,781,795 |
92,784,921 |
RGD:6480464 |
CTD |
| G |
Kcnn2 |
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
|
decreases activity |
EXP |
18 |
39,560,962 |
39,705,037 |
RGD:6480464 |
CTD |
| G |
Kcns1 |
potassium voltage-gated channel, delayed-rectifier, subfamily S, member 1 |
|
decreases expression |
EXP |
3 |
155,103,400 |
155,110,718 |
RGD:6480464 |
CTD |
| G |
Kcns3 |
potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 |
|
decreases expression |
EXP |
6 |
34,534,529 |
34,593,882 |
RGD:6480464 |
CTD |
| G |
LOC500300 |
similar to hypothetical protein MGC6835 |
|
increases expression |
ISO |
4 |
153,000,782 |
153,002,562 |
RGD:6480464 |
CTD |
| G |
LOC500300 |
similar to hypothetical protein MGC6835 |
|
increases expression |
ISO |
4 |
153,000,782 |
153,002,562 |
RGD:6480464 |
CTD |
| G |
LOC500300 |
similar to hypothetical protein MGC6835 |
|
increases expression |
ISO |
4 |
153,000,782 |
153,002,562 |
RGD:6480464 |
CTD |
| G |
Lox |
lysyl oxidase |
|
affects expression |
EXP |
18 |
47,896,674 |
47,970,829 |
RGD:6480464 |
CTD |
| G |
Lss |
lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) |
|
increases expression |
ISO |
20 |
12,507,575 |
12,534,612 |
RGD:6480464 |
CTD |
| G |
Lss |
lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) |
|
increases expression |
ISO |
20 |
12,507,575 |
12,534,612 |
RGD:6480464 |
CTD |
| G |
Lss |
lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) |
|
increases expression |
ISO |
20 |
12,507,575 |
12,534,612 |
RGD:6480464 |
CTD |
| G |
Manba |
mannosidase, beta A, lysosomal |
|
affects expression |
EXP |
2 |
232,983,989 |
233,077,788 |
RGD:6480464 |
CTD |
| G |
Maoa |
monoamine oxidase A |
|
affects expression |
EXP |
X |
17,678,960 |
17,745,908 |
RGD:6480464 |
CTD |
| G |
Mlx |
MLX, MAX dimerization protein |
|
affects expression |
EXP |
10 |
90,104,233 |
90,108,952 |
RGD:6480464 |
CTD |
| G |
Mmp16 |
matrix metallopeptidase 16 |
|
increases expression |
EXP |
5 |
32,352,311 |
32,586,469 |
RGD:6480464 |
CTD |
| G |
Mrps18b |
mitochondrial ribosomal protein S18B |
|
affects expression |
EXP |
20 |
2,985,972 |
2,992,031 |
RGD:6480464 |
CTD |
| G |
Msmo1 |
methylsterol monooxygenase 1 |
|
affects expression |
EXP |
16 |
26,698,324 |
26,716,247 |
RGD:6480464 |
CTD |
| G |
Nmb |
neuromedin B |
|
decreases expression |
EXP |
1 |
137,097,463 |
137,100,207 |
RGD:6480464 |
CTD |
| G |
Nmur1 |
neuromedin U receptor 1 |
|
decreases expression |
EXP |
9 |
85,146,808 |
85,148,380 |
RGD:6480464 |
CTD |
| G |
Nog |
noggin |
|
decreases expression |
EXP |
10 |
77,689,244 |
77,690,871 |
RGD:6480464 |
CTD |
| G |
Npy |
neuropeptide Y |
|
increases expression |
EXP |
4 |
78,038,013 |
78,045,187 |
RGD:6480464 |
CTD |
| G |
Npy5r |
neuropeptide Y receptor Y5 |
|
increases expression |
EXP |
16 |
24,765,175 |
24,773,132 |
RGD:6480464 |
CTD |
| G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
|
increases expression |
ISO |
5 |
151,524,685 |
151,528,000 |
RGD:6480464 |
CTD |
| G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
|
increases expression |
ISO |
5 |
151,524,685 |
151,528,000 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
affects response to substance |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
|
increases expression |
EXP |
19 |
32,527,752 |
32,875,369 |
RGD:6480464 |
CTD |
| G |
Nrep |
neuronal regeneration related protein |
|
affects expression |
EXP |
18 |
25,842,127 |
25,868,219 |
RGD:6480464 |
CTD |
| G |
Ntng1 |
netrin G1 |
|
decreases expression |
EXP |
2 |
205,438,061 |
205,806,249 |
RGD:6480464 |
CTD |
| G |
Nupr1 |
nuclear protein, transcriptional regulator, 1 |
|
increases expression |
ISO |
1 |
185,770,310 |
185,772,313 |
RGD:6480464 |
CTD |
| G |
Nupr1 |
nuclear protein, transcriptional regulator, 1 |
|
increases expression |
ISO |
1 |
185,770,310 |
185,772,313 |
RGD:6480464 |
CTD |
| G |
Nupr1 |
nuclear protein, transcriptional regulator, 1 |
|
increases expression |
ISO |
1 |
185,770,310 |
185,772,313 |
RGD:6480464 |
CTD |
| G |
Oaf |
OAF homolog (Drosophila) |
|
affects expression |
EXP |
8 |
46,224,861 |
46,242,832 |
RGD:6480464 |
CTD |
| G |
Pc |
pyruvate carboxylase |
|
affects expression |
EXP |
1 |
207,112,853 |
207,212,737 |
RGD:6480464 |
CTD |
| G |
Pecr |
peroxisomal trans-2-enoyl-CoA reductase |
|
affects expression |
EXP |
9 |
71,414,826 |
71,443,719 |
RGD:6480464 |
CTD |
| G |
Phyh |
phytanoyl-CoA 2-hydroxylase |
|
increases expression |
ISO |
17 |
84,418,173 |
84,435,073 |
RGD:6480464 |
CTD |
| G |
Plcd4 |
phospholipase C, delta 4 |
|
decreases expression |
EXP |
9 |
73,878,506 |
73,905,127 |
RGD:6480464 |
CTD |
| G |
Por |
P450 (cytochrome) oxidoreductase |
|
affects expression |
EXP |
12 |
22,078,629 |
22,097,301 |
RGD:6480464 |
CTD |
| G |
Ppapdc1a |
phosphatidic acid phosphatase type 2 domain containing 1A |
|
decreases expression |
EXP |
1 |
188,518,590 |
188,643,804 |
RGD:6480464 |
CTD |
| G |
Prokr1 |
prokineticin receptor 1 |
|
decreases expression |
EXP |
4 |
121,750,651 |
121,758,116 |
RGD:6480464 |
CTD |
| G |
Rasd1 |
RAS, dexamethasone-induced 1 |
|
increases expression |
EXP |
10 |
46,291,401 |
46,293,130 |
RGD:6480464 |
CTD |
| G |
Rbl2 |
retinoblastoma-like 2 |
|
affects expression |
EXP |
19 |
17,045,131 |
17,092,597 |
RGD:6480464 |
CTD |
| G |
Reg3b |
regenerating islet-derived 3 beta |
|
increases expression |
EXP |
4 |
112,355,773 |
112,359,011 |
RGD:6480464 |
CTD |
| G |
Rnf112 |
ring finger protein 112 |
|
decreases expression |
EXP |
10 |
47,599,958 |
47,605,503 |
RGD:6480464 |
CTD |
| G |
RT1-Da |
RT1 class II, locus Da |
|
increases expression |
EXP |
20 |
4,636,310 |
4,641,282 |
RGD:6480464 |
CTD |
| G |
RT1-Db1 |
RT1 class II, locus Db1 |
|
increases expression |
EXP |
20 |
4,671,489 |
4,681,058 |
RGD:6480464 |
CTD |
| G |
RT1-S3 |
RT1 class Ib, locus S3 |
|
affects expression |
EXP |
20 |
2,815,943 |
2,820,644 |
RGD:6480464 |
CTD |
| G |
Scd |
stearoyl-CoA desaturase (delta-9-desaturase) |
|
increases expression |
ISO |
1 |
249,358,105 |
249,371,164 |
RGD:6480464 |
CTD |
| G |
Scn11a |
sodium channel, voltage-gated, type XI, alpha subunit |
|
decreases expression |
EXP |
8 |
124,724,493 |
124,794,654 |
RGD:6480464 |
CTD |
| G |
Sema6a |
sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A |
|
increases expression |
EXP |
18 |
41,545,350 |
41,665,721 |
RGD:6480464 |
CTD |
| G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
|
increases expression |
ISO |
6 |
128,461,775 |
128,469,309 |
RGD:6480464 |
CTD |
| G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
|
increases expression |
ISO |
6 |
128,461,775 |
128,469,309 |
RGD:6480464 |
CTD |
| G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
|
increases expression |
ISO |
6 |
128,461,775 |
128,469,309 |
RGD:6480464 |
CTD |
| G |
Sh3gl3 |
SH3-domain GRB2-like 3 |
|
affects expression |
EXP |
1 |
138,398,336 |
138,529,056 |
RGD:6480464 |
CTD |
| G |
Slc22a6 |
solute carrier family 22 (organic anion transporter), member 6 |
|
multiple interactions |
ISO |
1 |
211,294,178 |
211,302,398 |
RGD:6480464 |
CTD |
| G |
Slc2a3 |
solute carrier family 2 (facilitated glucose transporter), member 3 |
|
decreases expression |
ISO |
4 |
159,210,116 |
159,221,169 |
RGD:6480464 |
CTD |
| G |
Slc2a3 |
solute carrier family 2 (facilitated glucose transporter), member 3 |
|
decreases expression |
ISO |
4 |
159,210,116 |
159,221,169 |
RGD:6480464 |
CTD |
| G |
Slc6a6 |
solute carrier family 6 (neurotransmitter transporter, taurine), member 6 |
|
affects expression |
EXP |
4 |
125,875,817 |
125,945,795 |
RGD:6480464 |
CTD |
| G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
|
affects expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Smagp |
small cell adhesion glycoprotein |
|
increases expression |
EXP |
7 |
139,367,386 |
139,403,817 |
RGD:6480464 |
CTD |
| G |
Sod1 |
superoxide dismutase 1, soluble |
|
increases expression |
EXP |
11 |
29,810,766 |
29,816,342 |
RGD:6480464 |
CTD |
| G |
Sox11 |
SRY (sex determining region Y)-box 11 |
|
increases expression |
EXP |
6 |
45,141,366 |
45,143,387 |
RGD:6480464 |
CTD |
| G |
Sprr1a |
small proline-rich protein 1A |
|
increases expression |
EXP |
2 |
185,463,951 |
185,465,849 |
RGD:6480464 |
CTD |
| G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
|
multiple interactions |
ISO |
10 |
46,461,684 |
46,483,646 |
RGD:6480464 |
CTD |
| G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
|
multiple interactions |
ISO |
7 |
120,522,511 |
120,580,212 |
RGD:6480464 |
CTD |
| G |
Sstr1 |
somatostatin receptor 1 |
|
decreases expression |
EXP |
6 |
78,803,393 |
78,806,978 |
RGD:6480464 |
CTD |
| G |
St13 |
suppression of tumorigenicity 13 |
|
affects expression |
EXP |
7 |
119,694,123 |
119,728,936 |
RGD:6480464 |
CTD |
| G |
Stac2 |
SH3 and cysteine rich domain 2 |
|
increases expression |
EXP |
10 |
86,799,903 |
86,816,382 |
RGD:6480464 |
CTD |
| G |
Stbd1 |
starch binding domain 1 |
|
affects expression |
EXP |
14 |
17,031,752 |
17,035,157 |
RGD:6480464 |
CTD |
| G |
Stmn1 |
stathmin 1 |
|
affects expression |
EXP |
5 |
153,226,420 |
153,232,084 |
RGD:6480464 |
CTD |
| G |
Stmn4 |
stathmin-like 4 |
|
increases expression |
EXP |
15 |
45,779,352 |
45,797,949 |
RGD:6480464 |
CTD |
| G |
Sult2a6 |
sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 6 |
|
affects expression |
EXP |
1 |
74,553,799 |
74,605,247 |
RGD:6480464 |
CTD |
| G |
Tagln |
transgelin |
|
decreases expression |
ISO |
8 |
48,902,208 |
48,907,682 |
RGD:6480464 |
CTD |
| G |
Tagln |
transgelin |
|
decreases expression |
ISO |
8 |
48,902,208 |
48,907,682 |
RGD:6480464 |
CTD |
| G |
Tagln |
transgelin |
|
decreases expression |
ISO |
8 |
48,902,208 |
48,907,682 |
RGD:6480464 |
CTD |
| G |
Tex261 |
testis expressed 261 |
|
affects expression |
EXP |
4 |
117,963,579 |
117,968,532 |
RGD:6480464 |
CTD |
| G |
Tgm1 |
transglutaminase 1 (K polypeptide epidermal type I, protein-glutamine-gamma-glutamyltransferase) |
|
increases expression |
EXP |
15 |
33,846,367 |
33,859,615 |
RGD:6480464 |
CTD |
| G |
Timm10b |
translocase of inner mitochondrial membrane 10 homolog B |
|
affects expression |
EXP |
1 |
163,369,731 |
163,372,577 |
RGD:6480464 |
CTD |
| G |
Trh |
thyrotropin releasing hormone |
|
multiple interactions |
ISO |
4 |
126,425,212 |
126,427,670 |
RGD:6480464 |
CTD |
| G |
Tshb |
thyroid stimulating hormone, beta |
|
multiple interactions |
ISO |
2 |
197,908,308 |
197,913,186 |
RGD:6480464 |
CTD |
| G |
Uba52 |
ubiquitin A-52 residue ribosomal protein fusion product 1 |
|
affects expression |
EXP |
16 |
19,425,401 |
19,427,557 |
RGD:6480464 |
CTD |
| G |
Ugt1a1 |
UDP glucuronosyltransferase 1 family, polypeptide A1 |
|
affects expression |
EXP |
9 |
87,091,241 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt2a1 |
UDP glucuronosyltransferase 2 family, polypeptide A1 |
|
affects expression |
EXP |
14 |
22,047,612 |
22,071,582 |
RGD:6480464 |
CTD |
| G |
Ugt2b17 |
UDP glucuronosyltransferase 2 family, polypeptide B17 |
|
affects expression |
EXP |
14 |
22,639,182 |
22,650,931 |
RGD:6480464 |
CTD |
| G |
Wipi1 |
WD repeat domain, phosphoinositide interacting 1 |
|
increases expression |
ISO |
10 |
98,722,266 |
98,753,713 |
RGD:6480464 |
CTD |
| G |
Wipi1 |
WD repeat domain, phosphoinositide interacting 1 |
|
increases expression |
ISO |
10 |
98,722,266 |
98,753,713 |
RGD:6480464 |
CTD |
azatadine
|
| G |
Hrh1 |
histamine receptor H 1 |
|
multiple interactions |
ISO |
4 |
150,431,239 |
150,432,699 |
RGD:6480464 |
CTD |
benzphetamine
|
| G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
|
increases metabolic processing |
ISO |
1 |
81,345,425 |
81,359,415 |
RGD:6480464 |
CTD |
| G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
|
increases metabolic processing |
ISO |
1 |
81,345,425 |
81,359,415 |
RGD:6480464 |
CTD |
bepridil
|
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Atf4 |
activating transcription factor 4 (tax-responsive enhancer element B67) |
|
increases expression |
ISO |
7 |
118,537,718 |
118,538,994 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
affects metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Ddit3 |
DNA-damage inducible transcript 3 |
|
increases expression |
ISO |
7 |
67,247,749 |
67,252,571 |
RGD:6480464 |
CTD |
| G |
Eif2a |
eukaryotic translation initiation factor 2A |
|
increases phosphorylation |
ISO |
2 |
147,870,265 |
147,903,411 |
RGD:6480464 |
CTD |
| G |
Kcna5 |
potassium voltage-gated channel, shaker-related subfamily, member 5 |
|
decreases activity |
ISO |
4 |
162,896,283 |
162,898,091 |
RGD:6480464 |
CTD |
| G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
|
multiple interactions |
ISO |
4 |
6,192,644 |
6,224,285 |
RGD:6480464 |
CTD |
| G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
|
decreases activity |
ISO |
4 |
6,192,644 |
6,224,285 |
RGD:6480464 |
CTD |
| G |
Slc8a1 |
solute carrier family 8 (sodium/calcium exchanger), member 1 |
|
multiple interactions |
ISO |
6 |
4,421,046 |
4,691,716 |
RGD:6480464 |
CTD |
| G |
Tnfrsf10b |
tumor necrosis factor receptor superfamily, member 10b |
|
increases expression |
ISO |
15 |
50,138,439 |
50,163,254 |
RGD:6480464 |
CTD |
| G |
Tnfsf10 |
tumor necrosis factor (ligand) superfamily, member 10 |
|
increases response to substance |
ISO |
2 |
113,204,303 |
113,221,550 |
RGD:6480464 |
CTD |
chlorpromazine
|
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases expression |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
|
affects activity |
EXP |
4 |
21,829,489 |
21,912,239 |
RGD:6480464 |
CTD |
| G |
Abcc3 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 3 |
|
increases expression |
ISO |
10 |
82,986,552 |
83,030,799 |
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Acp5 |
acid phosphatase 5, tartrate resistant |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Afp |
alpha-fetoprotein |
|
decreases expression |
ISO |
14 |
19,092,563 |
19,110,728 |
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
decreases phosphorylation |
EXP |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Alpp |
alkaline phosphatase, placental |
|
multiple interactions |
ISO |
9 |
85,885,336 |
85,888,082 |
RGD:6480464 |
CTD |
| G |
Ap1s1 |
adaptor-related protein complex 1, sigma 1 subunit |
|
decreases expression |
ISO |
12 |
20,907,855 |
20,918,301 |
RGD:6480464 |
CTD |
| G |
Areg |
amphiregulin |
|
decreases expression |
ISO |
14 |
18,466,313 |
18,475,571 |
RGD:6480464 |
CTD |
| G |
Asah1 |
N-acylsphingosine amidohydrolase (acid ceramidase) 1 |
|
increases expression |
ISO |
16 |
54,279,253 |
54,311,084 |
RGD:6480464 |
CTD |
| G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
|
increases expression |
ISO |
4 |
32,758,866 |
32,776,220 |
RGD:6480464 |
CTD |
| G |
Atp6v1b2 |
ATPase, H transporting, lysosomal V1 subunit B2 |
|
decreases expression |
EXP |
16 |
22,320,425 |
22,344,445 |
RGD:6480464 |
CTD |
| G |
Avp |
arginine vasopressin |
|
increases expression |
ISO |
3 |
118,205,007 |
118,206,985 |
RGD:6480464 |
CTD |
| G |
Avp |
arginine vasopressin |
|
multiple interactions |
EXP |
3 |
118,205,007 |
118,206,985 |
RGD:6480464 |
CTD |
| G |
Bag4 |
BCL2-associated athanogene 4 |
|
decreases expression |
ISO |
16 |
70,663,821 |
70,680,671 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
increases expression |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
affects response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
|
increases expression |
ISO |
4 |
144,139,486 |
144,145,186 |
RGD:6480464 |
CTD |
| G |
Birc5 |
baculoviral IAP repeat-containing 5 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Btg2 |
BTG family, member 2 |
|
increases expression |
ISO |
13 |
47,026,986 |
47,030,745 |
RGD:6480464 |
CTD |
| G |
Btg3 |
BTG family, member 3 |
|
increases expression |
ISO |
11 |
17,241,627 |
17,257,740 |
RGD:6480464 |
CTD |
| G |
Ca2 |
carbonic anhydrase 2 |
|
multiple interactions |
ISO |
2 |
88,077,095 |
88,092,223 |
RGD:6480464 |
CTD |
| G |
Calcr |
calcitonin receptor |
|
multiple interactions |
ISO |
4 |
28,486,176 |
28,561,296 |
RGD:6480464 |
CTD |
| G |
Calr |
calreticulin |
|
decreases expression |
EXP |
19 |
24,964,775 |
24,969,670 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
decreases activity |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
decreases expression |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Ccnb2 |
cyclin B2 |
|
decreases expression |
ISO |
8 |
74,892,108 |
74,906,181 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
decreases expression |
EXP |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd3 |
cyclin D3 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ccnf |
cyclin F |
|
decreases expression |
ISO |
10 |
13,474,659 |
13,500,979 |
RGD:6480464 |
CTD |
| G |
Cd86 |
CD86 molecule |
|
increases expression |
ISO |
11 |
66,215,233 |
66,238,882 |
RGD:6480464 |
CTD |
| G |
Cdk5 |
cyclin-dependent kinase 5 |
|
decreases expression |
ISO |
4 |
6,119,704 |
6,124,186 |
RGD:6480464 |
CTD |
| G |
Cdk7 |
cyclin-dependent kinase 7 |
|
increases expression |
ISO |
2 |
31,500,629 |
31,525,590 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
multiple interactions |
EXP |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
EXP |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
multiple interactions |
EXP |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) |
|
decreases expression |
ISO |
5 |
131,012,524 |
131,017,679 |
RGD:6480464 |
CTD |
| G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
|
decreases expression |
EXP |
6 |
25,414,812 |
25,426,818 |
RGD:6480464 |
CTD |
| G |
Chtf18 |
CTF18, chromosome transmission fidelity factor 18 homolog (S. cerevisiae) |
|
decreases expression |
ISO |
10 |
14,988,146 |
14,996,182 |
RGD:6480464 |
CTD |
| G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
|
decreases expression |
EXP |
1 |
12,721,500 |
12,723,943 |
RGD:6480464 |
CTD |
| G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
|
decreases expression |
ISO |
17 |
19,423,502 |
19,429,451 |
RGD:6480464 |
CTD |
| G |
Clcf1 |
cardiotrophin-like cytokine factor 1 |
|
increases expression |
ISO |
1 |
206,802,745 |
206,806,332 |
RGD:6480464 |
CTD |
| G |
Cox8a |
cytochrome c oxidase subunit VIIIa |
|
affects expression |
EXP |
1 |
209,886,141 |
209,888,462 |
RGD:6480464 |
CTD |
| G |
Cox8a |
cytochrome c oxidase subunit VIIIa |
|
increases expression |
EXP |
1 |
209,886,141 |
209,888,462 |
RGD:6480464 |
CTD |
| G |
Crh |
corticotropin releasing hormone |
|
decreases expression |
ISO |
2 |
104,764,023 |
104,765,887 |
RGD:6480464 |
CTD |
| G |
Ctsk |
cathepsin K |
|
multiple interactions |
ISO |
2 |
190,394,854 |
190,405,668 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
EXP |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases expression |
EXP |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases expression |
EXP |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
decreases methylation |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
affects expression |
EXP |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
increases oxidation |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
|
decreases activity |
ISO |
1 |
81,944,896 |
81,953,007 |
RGD:6480464 |
CTD |
| G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
|
multiple interactions |
ISO |
1 |
81,266,828 |
81,290,471 |
RGD:6480464 |
CTD |
| G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
|
multiple interactions |
ISO |
1 |
81,345,425 |
81,359,415 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
decreases expression |
EXP |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
decreases activity |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
multiple interactions |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
multiple interactions |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
decreases activity |
ISO |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
decreases activity |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
affects methylation |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
affects oxidation |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Dao |
D-amino-acid oxidase |
|
decreases activity |
ISO |
12 |
43,627,593 |
43,648,332 |
RGD:6480464 |
CTD |
| G |
Dcstamp |
dendrocyte expressed seven transmembrane protein |
|
multiple interactions |
ISO |
7 |
75,318,788 |
75,336,382 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
decreases response to substance |
ISO |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Dusp1 |
dual specificity phosphatase 1 |
|
increases expression |
ISO |
10 |
16,942,913 |
16,945,696 |
RGD:6480464 |
CTD |
| G |
Dusp1 |
dual specificity phosphatase 1 |
|
affects expression |
ISO |
10 |
16,942,913 |
16,945,696 |
RGD:6480464 |
CTD |
| G |
Dusp9 |
dual specificity phosphatase 9 |
|
decreases expression |
ISO |
X |
159,538,012 |
159,541,937 |
RGD:6480464 |
CTD |
| G |
E2f1 |
E2F transcription factor 1 |
|
decreases expression |
ISO |
3 |
145,032,489 |
145,043,729 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
increases expression |
EXP |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
multiple interactions |
EXP |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
decreases expression |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
Fabp1 |
fatty acid binding protein 1, liver |
|
increases expression |
ISO |
4 |
104,412,200 |
104,415,981 |
RGD:6480464 |
CTD |
| G |
Fabp1 |
fatty acid binding protein 1, liver |
|
increases expression |
ISO |
4 |
104,412,200 |
104,415,981 |
RGD:6480464 |
CTD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
increases expression |
ISO |
1 |
238,259,443 |
238,274,745 |
RGD:6480464 |
CTD |
| G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
|
decreases expression |
ISO |
16 |
70,869,974 |
70,910,045 |
RGD:6480464 |
CTD |
| G |
Fkbp5 |
FK506 binding protein 5 |
|
multiple interactions |
ISO |
20 |
6,637,478 |
6,686,768 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
affects expression |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fosb |
FBJ osteosarcoma oncogene B |
|
affects expression |
ISO |
1 |
78,668,497 |
78,673,330 |
RGD:6480464 |
CTD |
| G |
Fosl1 |
fos-like antigen 1 |
|
increases expression |
ISO |
1 |
208,090,612 |
208,099,118 |
RGD:6480464 |
CTD |
| G |
Fosl1 |
fos-like antigen 1 |
|
affects expression |
ISO |
1 |
208,090,612 |
208,099,118 |
RGD:6480464 |
CTD |
| G |
Fosl2 |
fos-like antigen 2 |
|
affects expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
G6pd |
glucose-6-phosphate dehydrogenase |
|
decreases expression |
ISO |
X |
160,186,450 |
160,192,316 |
RGD:6480464 |
CTD |
| G |
Gad1 |
glutamate decarboxylase 1 |
|
decreases methylation |
ISO |
3 |
52,789,370 |
52,830,038 |
RGD:6480464 |
CTD |
| G |
Gad1 |
glutamate decarboxylase 1 |
|
multiple interactions |
ISO |
3 |
52,789,370 |
52,830,038 |
RGD:6480464 |
CTD |
| G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
|
increases expression |
ISO |
1 |
185,941,893 |
185,984,348 |
RGD:6480464 |
CTD |
| G |
Gdpd3 |
glycerophosphodiester phosphodiesterase domain containing 3 |
|
increases expression |
ISO |
1 |
185,941,893 |
185,984,348 |
RGD:6480464 |
CTD |
| G |
Gsr |
glutathione reductase |
|
decreases activity |
EXP |
16 |
62,255,562 |
62,298,458 |
RGD:6480464 |
CTD |
| G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
increases expression |
ISO |
2 |
27,127,504 |
27,149,580 |
RGD:6480464 |
CTD |
| G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) |
|
increases expression |
ISO |
2 |
51,737,090 |
51,754,583 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
ISO |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hpn |
hepsin |
|
increases expression |
ISO |
1 |
86,145,615 |
86,161,091 |
RGD:6480464 |
CTD |
| G |
Hpn |
hepsin |
|
increases expression |
ISO |
1 |
86,145,615 |
86,161,091 |
RGD:6480464 |
CTD |
| G |
Ibsp |
integrin-binding sialoprotein |
|
decreases expression |
EXP |
14 |
6,548,541 |
6,561,165 |
RGD:6480464 |
CTD |
| G |
Ibsp |
integrin-binding sialoprotein |
|
multiple interactions |
EXP |
14 |
6,548,541 |
6,561,165 |
RGD:6480464 |
CTD |
| G |
Ifnlr1 |
interferon, lambda receptor 1 |
|
increases expression |
ISO |
5 |
154,461,523 |
154,480,844 |
RGD:6480464 |
CTD |
| G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
|
increases expression |
ISO |
14 |
87,950,222 |
87,955,289 |
RGD:6480464 |
CTD |
| G |
Ikbkg |
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma |
|
increases expression |
ISO |
X |
160,386,558 |
160,420,190 |
RGD:6480464 |
CTD |
| G |
Il1a |
interleukin 1 alpha |
|
multiple interactions |
ISO |
3 |
116,913,612 |
116,924,114 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
multiple interactions |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Inhbe |
inhibin beta E |
|
increases expression |
ISO |
7 |
67,308,713 |
67,310,138 |
RGD:6480464 |
CTD |
| G |
Inhbe |
inhibin beta E |
|
increases expression |
ISO |
7 |
67,308,713 |
67,310,138 |
RGD:6480464 |
CTD |
| G |
Ins1 |
insulin 1 |
|
decreases secretion |
EXP |
1 |
258,001,134 |
258,001,688 |
RGD:6480464 |
CTD |
| G |
Irs2 |
insulin receptor substrate 2 |
|
multiple interactions |
EXP |
16 |
83,379,987 |
83,404,220 |
RGD:6480464 |
CTD |
| G |
Irs2 |
insulin receptor substrate 2 |
|
multiple interactions |
EXP |
16 |
83,379,987 |
83,404,220 |
RGD:6480464 |
CTD |
| G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
|
decreases activity |
ISO |
4 |
6,192,644 |
6,224,285 |
RGD:6480464 |
CTD |
| G |
Kcnn2 |
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
|
decreases activity |
EXP |
18 |
39,560,962 |
39,705,037 |
RGD:6480464 |
CTD |
| G |
Ldlr |
low density lipoprotein receptor |
|
increases expression |
ISO |
8 |
20,824,040 |
20,846,920 |
RGD:6480464 |
CTD |
| G |
Lep |
leptin |
|
increases expression |
EXP |
4 |
55,943,837 |
55,945,938 |
RGD:6480464 |
CTD |
| G |
LOC500300 |
similar to hypothetical protein MGC6835 |
|
increases expression |
ISO |
4 |
153,000,782 |
153,002,562 |
RGD:6480464 |
CTD |
| G |
LOC500300 |
similar to hypothetical protein MGC6835 |
|
increases expression |
ISO |
4 |
153,000,782 |
153,002,562 |
RGD:6480464 |
CTD |
| G |
Lss |
lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) |
|
increases expression |
ISO |
20 |
12,507,575 |
12,534,612 |
RGD:6480464 |
CTD |
| G |
Lss |
lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) |
|
increases expression |
ISO |
20 |
12,507,575 |
12,534,612 |
RGD:6480464 |
CTD |
| G |
Map2 |
microtubule-associated protein 2 |
|
increases expression |
EXP |
9 |
65,174,376 |
65,256,003 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk14 |
mitogen activated protein kinase 14 |
|
decreases expression |
ISO |
20 |
6,939,249 |
7,000,378 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
decreases expression |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapkapk2 |
mitogen-activated protein kinase-activated protein kinase 2 |
|
increases expression |
EXP |
13 |
43,994,943 |
44,041,504 |
RGD:6480464 |
CTD |
| G |
Mcm3 |
minichromosome maintenance complex component 3 |
|
decreases expression |
ISO |
9 |
19,536,922 |
19,554,871 |
RGD:6480464 |
CTD |
| G |
Mcm5 |
minichromosome maintenance complex component 5 |
|
decreases expression |
ISO |
19 |
13,978,940 |
14,000,641 |
RGD:6480464 |
CTD |
| G |
Mki67 |
antigen identified by monoclonal antibody Ki-67 |
|
decreases expression |
ISO |
1 |
195,310,027 |
195,336,224 |
RGD:6480464 |
CTD |
| G |
Msh2 |
mutS homolog 2 (E. coli) |
|
decreases expression |
ISO |
6 |
11,199,906 |
11,258,350 |
RGD:6480464 |
CTD |
| G |
Mybl2 |
myeloblastosis oncogene-like 2 |
|
decreases expression |
ISO |
3 |
153,925,908 |
153,954,323 |
RGD:6480464 |
CTD |
| G |
Ndufs3 |
NADH dehydrogenase (ubiquinone) Fe-S protein 3 |
|
decreases expression |
EXP |
3 |
75,256,383 |
75,263,560 |
RGD:6480464 |
CTD |
| G |
Nfatc1 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 |
|
multiple interactions |
ISO |
18 |
77,498,654 |
77,581,231 |
RGD:6480464 |
CTD |
| G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
|
increases expression |
ISO |
5 |
151,524,685 |
151,528,000 |
RGD:6480464 |
CTD |
| G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
|
increases expression |
ISO |
11 |
64,239,918 |
64,276,702 |
RGD:6480464 |
CTD |
| G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
|
multiple interactions |
ISO |
11 |
64,239,918 |
64,276,702 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
increases activity |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
multiple interactions |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
multiple interactions |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
increases expression |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nupr1 |
nuclear protein, transcriptional regulator, 1 |
|
increases expression |
ISO |
1 |
185,770,310 |
185,772,313 |
RGD:6480464 |
CTD |
| G |
Nupr1 |
nuclear protein, transcriptional regulator, 1 |
|
increases expression |
ISO |
1 |
185,770,310 |
185,772,313 |
RGD:6480464 |
CTD |
| G |
Orc1 |
origin recognition complex, subunit 1 |
|
decreases expression |
ISO |
5 |
129,881,973 |
129,901,675 |
RGD:6480464 |
CTD |
| G |
Orm1 |
orosomucoid 1 |
|
affects binding |
ISO |
5 |
80,325,042 |
80,328,194 |
RGD:6480464 |
CTD |
| G |
Orm1 |
orosomucoid 1 |
|
multiple interactions |
ISO |
5 |
80,325,042 |
80,328,194 |
RGD:6480464 |
CTD |
| G |
Pdia2 |
protein disulfide isomerase family A, member 2 |
|
increases expression |
ISO |
10 |
15,462,935 |
15,466,009 |
RGD:6480464 |
CTD |
| G |
Phyh |
phytanoyl-CoA 2-hydroxylase |
|
increases expression |
ISO |
17 |
84,418,173 |
84,435,073 |
RGD:6480464 |
CTD |
| G |
Pias1 |
protein inhibitor of activated STAT, 1 |
|
increases expression |
ISO |
8 |
67,025,248 |
67,123,016 |
RGD:6480464 |
CTD |
| G |
Pim1 |
pim-1 oncogene |
|
increases expression |
ISO |
20 |
7,817,403 |
7,821,800 |
RGD:6480464 |
CTD |
| G |
Pola1 |
polymerase (DNA directed), alpha 1, catalytic subunit |
|
decreases expression |
ISO |
X |
80,650,454 |
80,965,833 |
RGD:6480464 |
CTD |
| G |
Pold4 |
polymerase (DNA-directed), delta 4, accessory subunit |
|
increases expression |
ISO |
1 |
206,815,462 |
206,817,131 |
RGD:6480464 |
CTD |
| G |
Prkaa1 |
protein kinase, AMP-activated, alpha 1 catalytic subunit |
|
decreases phosphorylation |
EXP |
2 |
54,327,821 |
54,360,462 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
increases expression |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
increases expression |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Rara |
retinoic acid receptor, alpha |
|
decreases expression |
EXP |
10 |
87,740,479 |
87,753,265 |
RGD:6480464 |
CTD |
| G |
Rxrg |
retinoid X receptor gamma |
|
affects response to substance |
ISO |
13 |
83,256,823 |
83,298,724 |
RGD:6480464 |
CTD |
| G |
Sc5d |
sterol-C5-desaturase |
|
increases expression |
ISO |
8 |
45,229,976 |
45,238,924 |
RGD:6480464 |
CTD |
| G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
|
increases expression |
ISO |
6 |
128,461,775 |
128,469,309 |
RGD:6480464 |
CTD |
| G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
|
increases expression |
ISO |
6 |
128,461,775 |
128,469,309 |
RGD:6480464 |
CTD |
| G |
Slc19a1 |
solute carrier family 19 (folate transporter), member 1 |
|
multiple interactions |
EXP |
20 |
11,984,283 |
12,001,865 |
RGD:6480464 |
CTD |
| G |
Slc19a1 |
solute carrier family 19 (folate transporter), member 1 |
|
decreases activity |
EXP |
20 |
11,984,283 |
12,001,865 |
RGD:6480464 |
CTD |
| G |
Slc2a3 |
solute carrier family 2 (facilitated glucose transporter), member 3 |
|
decreases expression |
ISO |
4 |
159,210,116 |
159,221,169 |
RGD:6480464 |
CTD |
| G |
Slc31a1 |
solute carrier family 31 (copper transporters), member 1 |
|
multiple interactions |
ISO |
5 |
79,359,420 |
79,385,988 |
RGD:6480464 |
CTD |
| G |
Sod1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
EXP |
11 |
29,810,766 |
29,816,342 |
RGD:6480464 |
CTD |
| G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
|
multiple interactions |
ISO |
7 |
120,522,511 |
120,580,212 |
RGD:6480464 |
CTD |
| G |
Sts |
steroid sulfatase (microsomal), isozyme S |
|
multiple interactions |
ISO |
X |
63,915,803 |
63,923,834 |
RGD:6480464 |
CTD |
| G |
Tagln |
transgelin |
|
decreases expression |
ISO |
8 |
48,902,208 |
48,907,682 |
RGD:6480464 |
CTD |
| G |
Tf |
transferrin |
|
affects localization |
ISO |
8 |
108,217,774 |
108,244,487 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases response to substance |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfrsf14 |
tumor necrosis factor receptor superfamily, member 14 |
|
increases expression |
ISO |
5 |
171,727,707 |
171,735,340 |
RGD:6480464 |
CTD |
| G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
|
multiple interactions |
ISO |
15 |
59,397,837 |
59,428,014 |
RGD:6480464 |
CTD |
| G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
|
decreases activity |
ISO |
15 |
59,397,837 |
59,428,014 |
RGD:6480464 |
CTD |
| G |
Ung |
uracil-DNA glycosylase |
|
decreases expression |
ISO |
12 |
43,520,629 |
43,528,873 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
increases expression |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Wipi1 |
WD repeat domain, phosphoinositide interacting 1 |
|
increases expression |
ISO |
10 |
98,722,266 |
98,753,713 |
RGD:6480464 |
CTD |
| G |
Wipi1 |
WD repeat domain, phosphoinositide interacting 1 |
|
increases expression |
ISO |
10 |
98,722,266 |
98,753,713 |
RGD:6480464 |
CTD |
| G |
Xrcc4 |
X-ray repair complementing defective repair in Chinese hamster cells 4 |
|
decreases expression |
ISO |
2 |
19,904,490 |
20,158,358 |
RGD:6480464 |
CTD |
chlorprothixene
|
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
multiple interactions |
ISO |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
increases secretion |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
cinchocaine
|
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases response to substance |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
clomiphene
|
| G |
Ar |
androgen receptor |
|
affects binding |
EXP |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
affects binding |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
affects binding |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
increases activity |
EXP |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
multiple interactions |
EXP |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
affects binding |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
F5 |
coagulation factor V (proaccelerin, labile factor) |
|
affects response to substance |
ISO |
13 |
79,934,956 |
79,997,285 |
RGD:6480464 |
CTD |
| G |
Fshb |
follicle stimulating hormone, beta polypeptide |
|
multiple interactions |
ISO |
3 |
92,569,344 |
92,571,254 |
RGD:6480464 |
CTD |
| G |
Fshb |
follicle stimulating hormone, beta polypeptide |
|
increases expression |
ISO |
3 |
92,569,344 |
92,571,254 |
RGD:6480464 |
CTD |
| G |
Gnrh1 |
gonadotropin-releasing hormone 1 (luteinizing-releasing hormone) |
|
multiple interactions |
ISO |
15 |
47,303,309 |
47,307,517 |
RGD:6480464 |
CTD |
| G |
Itgb3 |
integrin, beta 3 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Lhb |
luteinizing hormone beta |
|
increases secretion |
ISO |
1 |
95,892,999 |
95,893,988 |
RGD:6480464 |
CTD |
| G |
Lhb |
luteinizing hormone beta |
|
multiple interactions |
ISO |
1 |
95,892,999 |
95,893,988 |
RGD:6480464 |
CTD |
| G |
Lhb |
luteinizing hormone beta |
|
multiple interactions |
ISO |
1 |
95,892,999 |
95,893,988 |
RGD:6480464 |
CTD |
| G |
Pgr |
progesterone receptor |
|
increases expression |
ISO |
8 |
5,784,717 |
5,845,901 |
RGD:6480464 |
CTD |
| G |
Prkce |
protein kinase C, epsilon |
|
affects localization |
ISO |
6 |
9,631,234 |
10,097,311 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
cyproheptadine
|
| G |
Gh1 |
growth hormone 1 |
|
increases expression |
ISO |
10 |
95,692,240 |
95,694,117 |
RGD:6480464 |
CTD |
| G |
Kcnn2 |
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
|
decreases activity |
EXP |
18 |
39,560,962 |
39,705,037 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
decreases secretion |
ISO |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
decreases secretion |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Slc22a5 |
solute carrier family 22 (organic cation/carnitine transporter), member 5 |
|
multiple interactions |
ISO |
10 |
39,311,729 |
39,338,718 |
RGD:6480464 |
CTD |
dextropropoxyphene
|
| G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
|
affects response to substance |
ISO |
4 |
21,829,489 |
21,912,239 |
RGD:6480464 |
CTD |
| G |
Ces2h |
carboxylesterase 2H |
|
affects binding |
ISO |
19 |
34,910,981 |
34,925,547 |
RGD:6480464 |
CTD |
| G |
Oprd1 |
opioid receptor, delta 1 |
|
multiple interactions |
EXP |
5 |
150,979,252 |
151,014,066 |
RGD:6480464 |
CTD |
| G |
Oprd1 |
opioid receptor, delta 1 |
|
affects binding |
EXP |
5 |
150,979,252 |
151,014,066 |
RGD:6480464 |
CTD |
| G |
Oprk1 |
opioid receptor, kappa 1 |
|
multiple interactions |
EXP |
5 |
14,040,848 |
14,055,273 |
RGD:6480464 |
CTD |
| G |
Oprk1 |
opioid receptor, kappa 1 |
|
affects binding |
EXP |
5 |
14,040,848 |
14,055,273 |
RGD:6480464 |
CTD |
| G |
Oprm1 |
opioid receptor, mu 1 |
|
multiple interactions |
EXP |
1 |
37,535,416 |
37,779,392 |
RGD:6480464 |
CTD |
| G |
Oprm1 |
opioid receptor, mu 1 |
|
affects binding |
EXP |
1 |
37,535,416 |
37,779,392 |
RGD:6480464 |
CTD |
dimenhydrinate
|
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
diphenhydramine
|
| G |
Atg5 |
autophagy related 5 |
|
affects response to substance |
ISO |
20 |
48,273,977 |
48,366,743 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
multiple interactions |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
F3 |
coagulation factor III (thromboplastin, tissue factor) |
|
multiple interactions |
ISO |
2 |
218,371,050 |
218,382,645 |
RGD:6480464 |
CTD |
| G |
Gnai1 |
guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 |
|
increases response to substance |
ISO |
4 |
12,465,089 |
12,495,028 |
RGD:6480464 |
CTD |
| G |
Gnai2 |
guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 2 |
|
increases response to substance |
ISO |
8 |
112,861,952 |
112,882,647 |
RGD:6480464 |
CTD |
| G |
Hrh1 |
histamine receptor H 1 |
|
multiple interactions |
ISO |
4 |
150,431,239 |
150,432,699 |
RGD:6480464 |
CTD |
| G |
Hrh1 |
histamine receptor H 1 |
|
multiple interactions |
ISO |
4 |
150,431,239 |
150,432,699 |
RGD:6480464 |
CTD |
| G |
Hrh1 |
histamine receptor H 1 |
|
multiple interactions |
ISO |
4 |
150,431,239 |
150,432,699 |
RGD:6480464 |
CTD |
| G |
Hrh1 |
histamine receptor H 1 |
|
multiple interactions |
ISO |
4 |
150,431,239 |
150,432,699 |
RGD:6480464 |
CTD |
| G |
Hrh1 |
histamine receptor H 1 |
|
multiple interactions |
EXP |
4 |
150,431,239 |
150,432,699 |
RGD:6480464 |
CTD |
| G |
Hrh1 |
histamine receptor H 1 |
|
multiple interactions |
ISO |
4 |
150,431,239 |
150,432,699 |
RGD:6480464 |
CTD |
| G |
Hrh1 |
histamine receptor H 1 |
|
multiple interactions |
ISO |
4 |
150,431,239 |
150,432,699 |
RGD:6480464 |
CTD |
| G |
Hrh1 |
histamine receptor H 1 |
|
multiple interactions |
ISO |
4 |
150,431,239 |
150,432,699 |
RGD:6480464 |
CTD |
| G |
Hrh1 |
histamine receptor H 1 |
|
multiple interactions |
ISO |
4 |
150,431,239 |
150,432,699 |
RGD:6480464 |
CTD |
| G |
Hrh1 |
histamine receptor H 1 |
|
multiple interactions |
ISO |
4 |
150,431,239 |
150,432,699 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
increases activity |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
multiple interactions |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
|
multiple interactions |
ISO |
13 |
64,135,729 |
64,280,815 |
RGD:6480464 |
CTD |
| G |
Slc22a5 |
solute carrier family 22 (organic cation/carnitine transporter), member 5 |
|
multiple interactions |
ISO |
10 |
39,311,729 |
39,338,718 |
RGD:6480464 |
CTD |
diphenylpyraline
|
| G |
Hrh1 |
histamine receptor H 1 |
|
multiple interactions |
ISO |
4 |
150,431,239 |
150,432,699 |
RGD:6480464 |
CTD |
dipyridamole
|
| G |
Abcc4 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 4 |
|
decreases activity |
ISO |
15 |
103,384,848 |
103,611,238 |
RGD:6480464 |
CTD |
| G |
Abcc4 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 4 |
|
multiple interactions |
ISO |
15 |
103,384,848 |
103,611,238 |
RGD:6480464 |
CTD |
| G |
Adora3 |
adenosine A3 receptor |
|
increases expression |
EXP |
2 |
201,157,782 |
201,161,425 |
RGD:6480464 |
CTD |
| G |
Apoe |
apolipoprotein E |
|
multiple interactions |
ISO |
1 |
79,003,634 |
79,006,387 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
multiple interactions |
ISO |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Casp1 |
caspase 1 |
|
increases activity |
EXP |
8 |
2,027,976 |
2,036,872 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp7 |
caspase 7 |
|
increases activity |
ISO |
1 |
262,689,300 |
262,721,591 |
RGD:6480464 |
CTD |
| G |
Casp7 |
caspase 7 |
|
multiple interactions |
ISO |
1 |
262,689,300 |
262,721,591 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
multiple interactions |
ISO |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
ISO |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
multiple interactions |
EXP |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Cd40lg |
CD40 ligand |
|
decreases secretion |
ISO |
X |
141,925,019 |
141,937,183 |
RGD:6480464 |
CTD |
| G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
|
multiple interactions |
ISO |
9 |
57,309,836 |
57,356,635 |
RGD:6480464 |
CTD |
| G |
Cldn5 |
claudin 5 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Col1a1 |
collagen, type I, alpha 1 |
|
multiple interactions |
ISO |
10 |
83,622,438 |
83,639,368 |
RGD:6480464 |
CTD |
| G |
Col1a1 |
collagen, type I, alpha 1 |
|
decreases expression |
EXP |
10 |
83,622,438 |
83,639,368 |
RGD:6480464 |
CTD |
| G |
Col1a1 |
collagen, type I, alpha 1 |
|
decreases expression |
EXP |
10 |
83,622,438 |
83,639,368 |
RGD:6480464 |
CTD |
| G |
Cxcl12 |
chemokine (C-X-C motif) ligand 12 |
|
decreases expression |
ISO |
4 |
153,503,576 |
153,516,423 |
RGD:6480464 |
CTD |
| G |
Diablo |
diablo, IAP-binding mitochondrial protein |
|
multiple interactions |
ISO |
12 |
34,196,347 |
34,209,633 |
RGD:6480464 |
CTD |
| G |
Dusp1 |
dual specificity phosphatase 1 |
|
increases phosphorylation |
ISO |
10 |
16,942,913 |
16,945,696 |
RGD:6480464 |
CTD |
| G |
Dusp1 |
dual specificity phosphatase 1 |
|
multiple interactions |
ISO |
10 |
16,942,913 |
16,945,696 |
RGD:6480464 |
CTD |
| G |
Dusp1 |
dual specificity phosphatase 1 |
|
increases phosphorylation |
EXP |
10 |
16,942,913 |
16,945,696 |
RGD:6480464 |
CTD |
| G |
Dusp1 |
dual specificity phosphatase 1 |
|
multiple interactions |
EXP |
10 |
16,942,913 |
16,945,696 |
RGD:6480464 |
CTD |
| G |
Fadd |
Fas (TNFRSF6)-associated via death domain |
|
increases expression |
ISO |
1 |
205,010,363 |
205,012,768 |
RGD:6480464 |
CTD |
| G |
Fadd |
Fas (TNFRSF6)-associated via death domain |
|
multiple interactions |
ISO |
1 |
205,010,363 |
205,012,768 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
EXP |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
multiple interactions |
EXP |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
decreases expression |
ISO |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Ikbkb |
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta |
|
multiple interactions |
ISO |
16 |
73,804,730 |
73,858,510 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
decreases expression |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Insr |
insulin receptor |
|
multiple interactions |
ISO |
12 |
2,934,967 |
3,087,691 |
RGD:6480464 |
CTD |
| G |
Lep |
leptin |
|
multiple interactions |
EXP |
4 |
55,943,837 |
55,945,938 |
RGD:6480464 |
CTD |
| G |
Lep |
leptin |
|
increases expression |
EXP |
4 |
55,943,837 |
55,945,938 |
RGD:6480464 |
CTD |
| G |
LOC100360940 |
diablo-like |
|
multiple interactions |
ISO |
5 |
148,562,065 |
148,563,619 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
increases activity |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
ISO |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nppb |
natriuretic peptide B |
|
increases expression |
ISO |
5 |
165,062,348 |
165,063,650 |
RGD:6480464 |
CTD |
| G |
Orm1 |
orosomucoid 1 |
|
multiple interactions |
ISO |
5 |
80,325,042 |
80,328,194 |
RGD:6480464 |
CTD |
| G |
Orm1 |
orosomucoid 1 |
|
affects binding |
ISO |
5 |
80,325,042 |
80,328,194 |
RGD:6480464 |
CTD |
| G |
Pde10a |
phosphodiesterase 10A |
|
multiple interactions |
ISO |
1 |
46,392,900 |
46,589,076 |
RGD:6480464 |
CTD |
| G |
Pde11a |
phosphodiesterase 11A |
|
multiple interactions |
ISO |
3 |
58,659,595 |
59,049,869 |
RGD:6480464 |
CTD |
| G |
Pde4b |
phosphodiesterase 4B, cAMP specific |
|
increases expression |
ISO |
5 |
123,158,156 |
123,533,877 |
RGD:6480464 |
CTD |
| G |
Pde5a |
phosphodiesterase 5A, cGMP-specific |
|
decreases activity |
ISO |
2 |
219,410,394 |
219,550,910 |
RGD:6480464 |
CTD |
| G |
Pde7a |
phosphodiesterase 7A |
|
multiple interactions |
ISO |
2 |
104,339,910 |
104,429,820 |
RGD:6480464 |
CTD |
| G |
Pde7b |
phosphodiesterase 7B |
|
multiple interactions |
ISO |
1 |
15,701,127 |
15,929,632 |
RGD:6480464 |
CTD |
| G |
Pde7b |
phosphodiesterase 7B |
|
multiple interactions |
ISO |
1 |
15,701,127 |
15,929,632 |
RGD:6480464 |
CTD |
| G |
Pde7b |
phosphodiesterase 7B |
|
multiple interactions |
ISO |
1 |
15,701,127 |
15,929,632 |
RGD:6480464 |
CTD |
| G |
Pde7b |
phosphodiesterase 7B |
|
multiple interactions |
ISO |
1 |
15,701,127 |
15,929,632 |
RGD:6480464 |
CTD |
| G |
Pde8a |
phosphodiesterase 8A |
|
multiple interactions |
ISO |
1 |
137,415,852 |
137,544,337 |
RGD:6480464 |
CTD |
| G |
Pde8a |
phosphodiesterase 8A |
|
multiple interactions |
ISO |
1 |
137,415,852 |
137,544,337 |
RGD:6480464 |
CTD |
| G |
Pde8b |
phosphodiesterase 8B |
|
multiple interactions |
ISO |
2 |
25,352,725 |
25,469,209 |
RGD:6480464 |
CTD |
| G |
Pde8b |
phosphodiesterase 8B |
|
multiple interactions |
ISO |
2 |
25,352,725 |
25,469,209 |
RGD:6480464 |
CTD |
| G |
Plat |
plasminogen activator, tissue |
|
multiple interactions |
ISO |
16 |
73,711,323 |
73,736,328 |
RGD:6480464 |
CTD |
| G |
Plat |
plasminogen activator, tissue |
|
increases secretion |
ISO |
16 |
73,711,323 |
73,736,328 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
ISO |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
|
multiple interactions |
EXP |
13 |
64,427,288 |
64,432,978 |
RGD:6480464 |
CTD |
| G |
Rcan1 |
regulator of calcineurin 1 |
|
affects binding |
ISO |
11 |
32,386,576 |
32,408,850 |
RGD:6480464 |
CTD |
| G |
Slc29a1 |
solute carrier family 29 (nucleoside transporters), member 1 |
|
multiple interactions |
ISO |
9 |
11,000,054 |
11,014,914 |
RGD:6480464 |
CTD |
| G |
Slc29a1 |
solute carrier family 29 (nucleoside transporters), member 1 |
|
multiple interactions |
ISO |
9 |
11,000,054 |
11,014,914 |
RGD:6480464 |
CTD |
| G |
Slc29a1 |
solute carrier family 29 (nucleoside transporters), member 1 |
|
decreases activity |
ISO |
9 |
11,000,054 |
11,014,914 |
RGD:6480464 |
CTD |
| G |
Slc29a1 |
solute carrier family 29 (nucleoside transporters), member 1 |
|
multiple interactions |
ISO |
9 |
11,000,054 |
11,014,914 |
RGD:6480464 |
CTD |
| G |
Slc29a1 |
solute carrier family 29 (nucleoside transporters), member 1 |
|
multiple interactions |
ISO |
9 |
11,000,054 |
11,014,914 |
RGD:6480464 |
CTD |
| G |
Slc29a1 |
solute carrier family 29 (nucleoside transporters), member 1 |
|
multiple interactions |
ISO |
9 |
11,000,054 |
11,014,914 |
RGD:6480464 |
CTD |
| G |
Slc29a1 |
solute carrier family 29 (nucleoside transporters), member 1 |
|
multiple interactions |
ISO |
9 |
11,000,054 |
11,014,914 |
RGD:6480464 |
CTD |
| G |
Slc29a2 |
solute carrier family 29 (nucleoside transporters), member 2 |
|
multiple interactions |
ISO |
1 |
207,643,719 |
207,650,360 |
RGD:6480464 |
CTD |
| G |
Slc29a2 |
solute carrier family 29 (nucleoside transporters), member 2 |
|
multiple interactions |
ISO |
1 |
207,643,719 |
207,650,360 |
RGD:6480464 |
CTD |
| G |
Slc4a1 |
solute carrier family 4 (anion exchanger), member 1 |
|
multiple interactions |
ISO |
10 |
91,454,824 |
91,471,072 |
RGD:6480464 |
CTD |
| G |
Spp1 |
secreted phosphoprotein 1 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Spp1 |
secreted phosphoprotein 1 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
ISO |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Th |
tyrosine hydroxylase |
|
decreases expression |
EXP |
1 |
203,164,253 |
203,171,506 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Txn1 |
thioredoxin 1 |
|
multiple interactions |
EXP |
5 |
75,921,365 |
75,933,595 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
decreases expression |
ISO |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
increases secretion |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
| G |
Vegfa |
vascular endothelial growth factor A |
|
multiple interactions |
ISO |
9 |
10,520,730 |
10,536,071 |
RGD:6480464 |
CTD |
disopyramide
|
| G |
Asah1 |
N-acylsphingosine amidohydrolase (acid ceramidase) 1 |
|
increases expression |
ISO |
16 |
54,279,253 |
54,311,084 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
|
decreases activity |
ISO |
4 |
6,192,644 |
6,224,285 |
RGD:6480464 |
CTD |
| G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
|
multiple interactions |
ISO |
4 |
6,192,644 |
6,224,285 |
RGD:6480464 |
CTD |
| G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
|
decreases expression |
ISO |
5 |
151,524,685 |
151,528,000 |
RGD:6480464 |
CTD |
| G |
Slc22a1 |
solute carrier family 22 (organic cation transporter), member 1 |
|
multiple interactions |
EXP |
1 |
42,351,239 |
42,378,295 |
RGD:6480464 |
CTD |
| G |
Slc22a2 |
solute carrier family 22 (organic cation transporter), member 2 |
|
multiple interactions |
EXP |
1 |
42,395,676 |
42,442,847 |
RGD:6480464 |
CTD |
doxylamine
|
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
multiple interactions |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
methadone
|
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
affects activity |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases expression |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
|
increases expression |
EXP |
4 |
21,829,489 |
21,912,239 |
RGD:6480464 |
CTD |
| G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
|
affects activity |
EXP |
4 |
21,829,489 |
21,912,239 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
affects localization |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
increases secretion |
EXP |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl3 |
chemokine (C-C motif) ligand 3 |
|
increases secretion |
EXP |
10 |
71,744,559 |
71,746,109 |
RGD:6480464 |
CTD |
| G |
Cx3cl1 |
chemokine (C-X3-C motif) ligand 1 |
|
increases secretion |
EXP |
19 |
10,666,940 |
10,676,424 |
RGD:6480464 |
CTD |
| G |
Cxcl1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
increases secretion |
EXP |
14 |
18,690,339 |
18,692,118 |
RGD:6480464 |
CTD |
| G |
Cycs |
cytochrome c, somatic |
|
affects localization |
ISO |
4 |
78,825,878 |
78,827,978 |
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
|
affects metabolic processing |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
affects metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
multiple interactions |
EXP |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Hcrt |
hypocretin |
|
multiple interactions |
EXP |
10 |
89,699,633 |
89,700,847 |
RGD:6480464 |
CTD |
| G |
Il10 |
interleukin 10 |
|
increases secretion |
EXP |
13 |
43,953,900 |
43,957,766 |
RGD:6480464 |
CTD |
| G |
Il1a |
interleukin 1 alpha |
|
increases expression |
EXP |
3 |
116,913,612 |
116,924,114 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases secretion |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases secretion |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Ins2 |
insulin 2 |
|
decreases response to substance |
ISO |
1 |
202,935,548 |
202,936,379 |
RGD:6480464 |
CTD |
| G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
|
multiple interactions |
ISO |
4 |
6,192,644 |
6,224,285 |
RGD:6480464 |
CTD |
| G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
|
decreases activity |
ISO |
4 |
6,192,644 |
6,224,285 |
RGD:6480464 |
CTD |
| G |
Lep |
leptin |
|
increases expression |
ISO |
4 |
55,943,837 |
55,945,938 |
RGD:6480464 |
CTD |
| G |
Oprd1 |
opioid receptor, delta 1 |
|
affects binding |
EXP |
5 |
150,979,252 |
151,014,066 |
RGD:6480464 |
CTD |
| G |
Oprd1 |
opioid receptor, delta 1 |
|
multiple interactions |
EXP |
5 |
150,979,252 |
151,014,066 |
RGD:6480464 |
CTD |
| G |
Oprk1 |
opioid receptor, kappa 1 |
|
affects binding |
EXP |
5 |
14,040,848 |
14,055,273 |
RGD:6480464 |
CTD |
| G |
Oprk1 |
opioid receptor, kappa 1 |
|
multiple interactions |
EXP |
5 |
14,040,848 |
14,055,273 |
RGD:6480464 |
CTD |
| G |
Oprm1 |
opioid receptor, mu 1 |
|
multiple interactions |
EXP |
1 |
37,535,416 |
37,779,392 |
RGD:6480464 |
CTD |
| G |
Oprm1 |
opioid receptor, mu 1 |
|
affects binding |
EXP |
1 |
37,535,416 |
37,779,392 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
affects secretion |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
increases expression |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
increases secretion |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Tlr4 |
toll-like receptor 4 |
|
affects binding |
ISO |
5 |
83,564,100 |
83,577,735 |
RGD:6480464 |
CTD |
| G |
Tlr4 |
toll-like receptor 4 |
|
multiple interactions |
ISO |
5 |
83,564,100 |
83,577,735 |
RGD:6480464 |
CTD |
| G |
Tlr4 |
toll-like receptor 4 |
|
affects response to substance |
EXP |
5 |
83,564,100 |
83,577,735 |
RGD:6480464 |
CTD |
| G |
Tlr4 |
toll-like receptor 4 |
|
increases expression |
EXP |
5 |
83,564,100 |
83,577,735 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases secretion |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
N(6),N(6)-dimethyladenine
|
| G |
A2m |
alpha-2-macroglobulin |
|
multiple interactions |
EXP |
4 |
158,103,711 |
158,153,423 |
RGD:6480464 |
CTD |
| G |
Cdh1 |
cadherin 1 |
|
multiple interactions |
EXP |
19 |
36,442,693 |
36,512,091 |
RGD:6480464 |
CTD |
| G |
Cdh2 |
cadherin 2 |
|
multiple interactions |
EXP |
18 |
8,048,920 |
8,267,974 |
RGD:6480464 |
CTD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
multiple interactions |
EXP |
8 |
125,978,161 |
125,987,670 |
RGD:6480464 |
CTD |
| G |
Lig1 |
ligase I, DNA, ATP-dependent |
|
multiple interactions |
ISO |
1 |
73,728,892 |
73,767,429 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
EXP |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk9 |
mitogen-activated protein kinase 9 |
|
multiple interactions |
EXP |
10 |
35,353,486 |
35,384,319 |
RGD:6480464 |
CTD |
| G |
Ocln |
occludin |
|
multiple interactions |
EXP |
2 |
31,317,090 |
31,367,485 |
RGD:6480464 |
CTD |
| G |
Tjp1 |
tight junction protein 1 |
|
multiple interactions |
EXP |
1 |
119,684,774 |
119,750,532 |
RGD:6480464 |
CTD |
N,N-dimethyl-4-nitrosoaniline
|
| G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
|
decreases expression |
ISO |
1 |
196,629,366 |
196,866,937 |
RGD:6480464 |
CTD |
| G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
|
decreases expression |
EXP |
1 |
196,629,366 |
196,866,937 |
RGD:6480464 |
CTD |
N,N-dimethylethanolamine
|
| G |
Ar |
androgen receptor |
|
multiple interactions |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
oxybutynin
|
| G |
Abcb11 |
ATP-binding cassette, subfamily B (MDR/TAP), member 11 |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ces2h |
carboxylesterase 2H |
|
increases hydrolysis |
ISO |
19 |
34,910,981 |
34,925,547 |
RGD:6480464 |
CTD |
| G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
|
multiple interactions |
ISO |
4 |
63,911,292 |
63,913,354 |
RGD:6480464 |
CTD |
| G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
|
multiple interactions |
ISO |
17 |
71,214,906 |
71,218,463 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
decreases activity |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
affects binding |
ISO |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
decreases expression |
EXP |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
procaine
|
| G |
Alpl |
alkaline phosphatase, liver/bone/kidney |
|
increases expression |
ISO |
5 |
156,501,739 |
156,558,727 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
increases secretion |
ISO |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Casp12 |
caspase 12 |
|
multiple interactions |
ISO |
8 |
2,082,933 |
2,110,511 |
RGD:6480464 |
CTD |
| G |
Ces2h |
carboxylesterase 2H |
|
increases hydrolysis |
ISO |
19 |
34,910,981 |
34,925,547 |
RGD:6480464 |
CTD |
| G |
Ces2h |
carboxylesterase 2H |
|
increases hydrolysis |
ISO |
19 |
34,910,981 |
34,925,547 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
increases expression |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
|
increases activity |
EXP |
10 |
60,109,656 |
60,134,939 |
RGD:6480464 |
CTD |
promazine
|
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Crh |
corticotropin releasing hormone |
|
decreases expression |
ISO |
2 |
104,764,023 |
104,765,887 |
RGD:6480464 |
CTD |
promethazine
|
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
ISO |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Bche |
butyrylcholinesterase |
|
decreases activity |
EXP |
2 |
164,329,613 |
164,427,994 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
decreases metabolic processing |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
decreases metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Hrh1 |
histamine receptor H 1 |
|
multiple interactions |
ISO |
4 |
150,431,239 |
150,432,699 |
RGD:6480464 |
CTD |
| G |
Hrh1 |
histamine receptor H 1 |
|
multiple interactions |
ISO |
4 |
150,431,239 |
150,432,699 |
RGD:6480464 |
CTD |
| G |
Hrh2 |
histamine receptor H 2 |
|
multiple interactions |
ISO |
17 |
16,497,967 |
16,499,043 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Ngf |
nerve growth factor (beta polypeptide) |
|
multiple interactions |
EXP |
2 |
197,621,726 |
197,632,960 |
RGD:6480464 |
CTD |
| G |
Slc22a5 |
solute carrier family 22 (organic cation/carnitine transporter), member 5 |
|
multiple interactions |
ISO |
10 |
39,311,729 |
39,338,718 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfsf11 |
tumor necrosis factor (ligand) superfamily, member 11 |
|
decreases activity |
ISO |
15 |
59,397,837 |
59,428,014 |
RGD:6480464 |
CTD |
ropinirole
|
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
multiple interactions |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
multiple interactions |
ISO |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Drd3 |
dopamine receptor D3 |
|
multiple interactions |
ISO |
11 |
58,446,901 |
58,520,589 |
RGD:6480464 |
CTD |
| G |
Drd3 |
dopamine receptor D3 |
|
multiple interactions |
ISO |
11 |
58,446,901 |
58,520,589 |
RGD:6480464 |
CTD |
| G |
Drd4 |
dopamine receptor D4 |
|
multiple interactions |
ISO |
1 |
201,485,597 |
201,488,784 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
decreases expression |
EXP |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases phosphorylation |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases phosphorylation |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
tolterodine
|
| G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
|
multiple interactions |
ISO |
4 |
63,911,292 |
63,913,354 |
RGD:6480464 |
CTD |
| G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
|
multiple interactions |
ISO |
17 |
71,214,906 |
71,218,463 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
multiple interactions |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
increases metabolic processing |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
multiple interactions |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
increases metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
toremifene
|
| G |
Ar |
androgen receptor |
|
decreases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr2 |
estrogen receptor 2 (ER beta) |
|
increases expression |
ISO |
6 |
98,691,167 |
98,775,299 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Gsta1 |
glutathione S-transferase alpha 1 |
|
decreases expression |
EXP |
9 |
20,051,501 |
20,068,146 |
RGD:6480464 |
CTD |
| G |
Il1a |
interleukin 1 alpha |
|
multiple interactions |
ISO |
3 |
116,913,612 |
116,924,114 |
RGD:6480464 |
CTD |
| G |
Serpinc1 |
serpin peptidase inhibitor, clade C (antithrombin), member 1 |
|
decreases expression |
ISO |
13 |
76,548,456 |
76,562,724 |
RGD:6480464 |
CTD |
| G |
Shbg |
sex hormone binding globulin |
|
increases expression |
ISO |
10 |
56,432,474 |
56,435,654 |
RGD:6480464 |
CTD |
triethanolamine
|
| G |
Kcnk18 |
potassium channel, subfamily K, member 18 |
|
multiple interactions |
ISO |
1 |
265,749,192 |
265,764,641 |
RGD:6480464 |
CTD |
trimethylamine
|
| G |
Fmo3 |
flavin containing monooxygenase 3 |
|
affects metabolic processing |
ISO |
13 |
78,659,513 |
78,678,524 |
RGD:6480464 |
CTD |
| G |
Fmo3 |
flavin containing monooxygenase 3 |
|
increases metabolic processing |
ISO |
13 |
78,659,513 |
78,678,524 |
RGD:6480464 |
CTD |
| G |
Fmo3 |
flavin containing monooxygenase 3 |
|
increases oxidation |
ISO |
13 |
78,659,513 |
78,678,524 |
RGD:6480464 |
CTD |
| G |
Fmo3 |
flavin containing monooxygenase 3 |
|
increases oxidation |
EXP |
13 |
78,659,513 |
78,678,524 |
RGD:6480464 |
CTD |
| G |
Fmo3 |
flavin containing monooxygenase 3 |
|
increases oxidation |
ISO |
13 |
78,659,513 |
78,678,524 |
RGD:6480464 |
CTD |
| G |
Fmo3 |
flavin containing monooxygenase 3 |
|
multiple interactions |
EXP |
13 |
78,659,513 |
78,678,524 |
RGD:6480464 |
CTD |
| G |
Fmo3 |
flavin containing monooxygenase 3 |
|
affects metabolic processing |
ISO |
13 |
78,659,513 |
78,678,524 |
RGD:6480464 |
CTD |
| G |
Fmo3 |
flavin containing monooxygenase 3 |
|
increases metabolic processing |
ISO |
13 |
78,659,513 |
78,678,524 |
RGD:6480464 |
CTD |
| G |
Fmo3 |
flavin containing monooxygenase 3 |
|
increases metabolic processing |
ISO |
13 |
78,659,513 |
78,678,524 |
RGD:6480464 |
CTD |
| G |
Fmo3 |
flavin containing monooxygenase 3 |
|
increases metabolic processing |
ISO |
13 |
78,659,513 |
78,678,524 |
RGD:6480464 |
CTD |
| G |
Fmo3 |
flavin containing monooxygenase 3 |
|
increases metabolic processing |
ISO |
13 |
78,659,513 |
78,678,524 |
RGD:6480464 |
CTD |
| G |
Slco1a1 |
solute carrier organic anion transporter family, member 1a1 |
|
affects abundance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
|
affects abundance |
ISO |
|
|
|
RGD:6480464 |
CTD |
trimethylamine N-oxide
|
| G |
Mbp |
myelin basic protein |
|
multiple interactions |
ISO |
18 |
78,943,608 |
79,057,329 |
RGD:6480464 |
CTD |
| G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
|
affects abundance |
ISO |
|
|
|
RGD:6480464 |
CTD |
venlafaxine
|
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases expression |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases export |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
increases expression |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Acp5 |
acid phosphatase 5, tartrate resistant |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Akt1 |
v-akt murine thymoma viral oncogene homolog 1 |
|
increases expression |
EXP |
6 |
137,640,482 |
137,657,552 |
RGD:6480464 |
CTD |
| G |
Ankrd55 |
ankyrin repeat domain 55 |
|
increases expression |
ISO |
2 |
43,547,129 |
43,701,247 |
RGD:6480464 |
CTD |
| G |
Arc |
activity-regulated cytoskeleton-associated protein |
|
increases expression |
EXP |
7 |
112,771,937 |
112,775,381 |
RGD:6480464 |
CTD |
| G |
Arc |
activity-regulated cytoskeleton-associated protein |
|
increases expression |
EXP |
7 |
112,771,937 |
112,775,381 |
RGD:6480464 |
CTD |
| G |
Arc |
activity-regulated cytoskeleton-associated protein |
|
increases expression |
EXP |
7 |
112,771,937 |
112,775,381 |
RGD:6480464 |
CTD |
| G |
Arhgap10 |
Rho GTPase activating protein 10 |
|
increases expression |
ISO |
19 |
32,261,771 |
32,521,913 |
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Ctnnb1 |
catenin (cadherin associated protein), beta 1 |
|
increases expression |
EXP |
8 |
125,978,161 |
125,987,670 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
decreases methylation |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
affects metabolic processing |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
decreases activity |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
affects response to substance |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
affects metabolic processing |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
affects methylation |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
|
increases metabolic processing |
ISO |
7 |
120,778,783 |
120,783,140 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
affects metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
affects metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
affects methylation |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
affects response to substance |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
decreases methylation |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
increases metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
decreases activity |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
affects metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
affects methylation |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
increases metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
decreases methylation |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
increases metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
increases metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
increases metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
|
increases metabolic processing |
ISO |
7 |
120,742,273 |
120,752,274 |
RGD:6480464 |
CTD |
| G |
Fam5c |
family with sequence similarity 5, member C |
|
increases expression |
ISO |
13 |
60,584,348 |
61,024,196 |
RGD:6480464 |
CTD |
| G |
Fmnl1 |
formin-like 1 |
|
increases expression |
ISO |
10 |
92,343,548 |
92,384,092 |
RGD:6480464 |
CTD |
| G |
Kcnj3 |
potassium inwardly-rectifying channel, subfamily J, member 3 |
|
multiple interactions |
ISO |
3 |
37,068,672 |
37,256,990 |
RGD:6480464 |
CTD |
| G |
Kcnj5 |
potassium inwardly-rectifying channel, subfamily J, member 5 |
|
multiple interactions |
ISO |
8 |
32,082,866 |
32,104,412 |
RGD:6480464 |
CTD |
| G |
Kcnj6 |
potassium inwardly-rectifying channel, subfamily J, member 6 |
|
multiple interactions |
ISO |
11 |
35,025,118 |
35,116,500 |
RGD:6480464 |
CTD |
| G |
Klk10 |
kallikrein related-peptidase 10 |
|
decreases expression |
ISO |
1 |
94,210,924 |
94,214,301 |
RGD:6480464 |
CTD |
| G |
Large |
like-glycosyltransferase |
|
decreases expression |
ISO |
19 |
12,043,818 |
12,497,663 |
RGD:6480464 |
CTD |
| G |
Lipg |
lipase, endothelial |
|
increases expression |
ISO |
18 |
71,795,150 |
71,816,056 |
RGD:6480464 |
CTD |
| G |
Lmo7 |
LIM domain 7 |
|
decreases expression |
ISO |
15 |
85,710,975 |
85,928,469 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
increases phosphorylation |
EXP |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
increases phosphorylation |
EXP |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mvp |
major vault protein |
|
decreases expression |
ISO |
1 |
186,164,811 |
186,192,802 |
RGD:6480464 |
CTD |
| G |
Nasp |
nuclear autoantigenic sperm protein (histone-binding) |
|
increases expression |
ISO |
5 |
136,884,705 |
136,910,192 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
decreases expression |
EXP |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
|
decreases expression |
EXP |
19 |
32,527,752 |
32,875,369 |
RGD:6480464 |
CTD |
| G |
Nsun2 |
NOP2/Sun RNA methyltransferase family, member 2 |
|
decreases expression |
ISO |
17 |
3,820,859 |
3,844,582 |
RGD:6480464 |
CTD |
| G |
Prex2 |
phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2 |
|
decreases expression |
ISO |
5 |
7,404,475 |
7,693,459 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
increases expression |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Rcc1 |
regulator of chromosome condensation 1 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
RGD1309148 |
similar to RIKEN cDNA 3110001D03 |
|
increases expression |
ISO |
5 |
93,253,890 |
93,254,986 |
RGD:6480464 |
CTD |
| G |
Ring1 |
ring finger protein 1 |
|
increases expression |
ISO |
20 |
4,968,251 |
4,972,149 |
RGD:6480464 |
CTD |
| G |
Sall1 |
sal-like 1 (Drosophila) |
|
increases expression |
ISO |
19 |
19,277,337 |
19,293,298 |
RGD:6480464 |
CTD |
| G |
Serpini1 |
serpin peptidase inhibitor, clade I (neuroserpin), member 1 |
|
increases expression |
EXP |
2 |
166,445,765 |
166,555,032 |
RGD:6480464 |
CTD |
| G |
Slc6a4 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
|
affects response to substance |
ISO |
10 |
67,134,790 |
67,155,891 |
RGD:6480464 |
CTD |
| G |
Sod1 |
superoxide dismutase 1, soluble |
|
increases expression |
EXP |
11 |
29,810,766 |
29,816,342 |
RGD:6480464 |
CTD |
| G |
Syp |
synaptophysin |
|
increases expression |
EXP |
X |
26,890,307 |
26,905,319 |
RGD:6480464 |
CTD |
| G |
Syt4 |
synaptotagmin IV |
|
increases expression |
ISO |
18 |
23,805,080 |
23,814,489 |
RGD:6480464 |
CTD |
| G |
Tcf12 |
transcription factor 12 |
|
decreases expression |
ISO |
8 |
76,311,327 |
76,498,091 |
RGD:6480464 |
CTD |
| G |
Trim13 |
tripartite motif-containing 13 |
|
decreases expression |
ISO |
15 |
40,743,520 |
40,752,138 |
RGD:6480464 |
CTD |
| G |
Ube2q1 |
ubiquitin-conjugating enzyme E2Q family member 1 |
|
decreases expression |
ISO |
2 |
181,978,842 |
181,987,913 |
RGD:6480464 |
CTD |
verapamil
|
| G |
Abca8 |
ATP-binding cassette, subfamily A (ABC1), member 8 |
|
multiple interactions |
ISO |
10 |
99,392,053 |
99,452,833 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases activity |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases activity |
EXP |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases activity |
EXP |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases activity |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases expression |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases activity |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases expression |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases activity |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases activity |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases expression |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases activity |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases activity |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
EXP |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases activity |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases expression |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
|
affects response to substance |
ISO |
4 |
21,829,489 |
21,912,239 |
RGD:6480464 |
CTD |
| G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
|
decreases activity |
EXP |
4 |
21,829,489 |
21,912,239 |
RGD:6480464 |
CTD |
| G |
Abcb4 |
ATP-binding cassette, subfamily B (MDR/TAP), member 4 |
|
decreases activity |
EXP |
4 |
21,946,274 |
22,004,328 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
affects activity |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
multiple interactions |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
multiple interactions |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
multiple interactions |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
decreases activity |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
multiple interactions |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
decreases activity |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcc3 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 3 |
|
multiple interactions |
ISO |
10 |
82,986,552 |
83,030,799 |
RGD:6480464 |
CTD |
| G |
Abcc6 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 6 |
|
decreases activity |
ISO |
1 |
96,448,588 |
96,524,655 |
RGD:6480464 |
CTD |
| G |
Adra1a |
adrenoceptor alpha 1A |
|
multiple interactions |
ISO |
15 |
46,173,429 |
46,263,198 |
RGD:6480464 |
CTD |
| G |
Adra1a |
adrenoceptor alpha 1A |
|
affects binding |
ISO |
15 |
46,173,429 |
46,263,198 |
RGD:6480464 |
CTD |
| G |
Adra1b |
adrenoceptor alpha 1B |
|
affects binding |
ISO |
10 |
28,889,092 |
28,946,889 |
RGD:6480464 |
CTD |
| G |
Adra1b |
adrenoceptor alpha 1B |
|
multiple interactions |
ISO |
10 |
28,889,092 |
28,946,889 |
RGD:6480464 |
CTD |
| G |
Adra1d |
adrenoceptor alpha 1D |
|
multiple interactions |
ISO |
3 |
119,279,974 |
119,295,985 |
RGD:6480464 |
CTD |
| G |
Adra1d |
adrenoceptor alpha 1D |
|
affects binding |
ISO |
3 |
119,279,974 |
119,295,985 |
RGD:6480464 |
CTD |
| G |
Adrb1 |
adrenoceptor beta 1 |
|
affects response to substance |
ISO |
1 |
263,025,655 |
263,027,055 |
RGD:6480464 |
CTD |
| G |
Cacna1c |
calcium channel, voltage-dependent, L type, alpha 1C subunit |
|
increases response to substance |
ISO |
4 |
154,895,691 |
155,517,389 |
RGD:6480464 |
CTD |
| G |
Cacna1c |
calcium channel, voltage-dependent, L type, alpha 1C subunit |
|
multiple interactions |
EXP |
4 |
154,895,691 |
155,517,389 |
RGD:6480464 |
CTD |
| G |
Cacna1c |
calcium channel, voltage-dependent, L type, alpha 1C subunit |
|
decreases expression |
EXP |
4 |
154,895,691 |
155,517,389 |
RGD:6480464 |
CTD |
| G |
Cacna1f |
calcium channel, voltage-dependent, L type, alpha 1F subunit |
|
multiple interactions |
ISO |
X |
26,908,850 |
26,937,165 |
RGD:6480464 |
CTD |
| G |
Cacna1h |
calcium channel, voltage-dependent, T type, alpha 1H subunit |
|
multiple interactions |
EXP |
10 |
14,621,372 |
14,679,051 |
RGD:6480464 |
CTD |
| G |
Cacna1h |
calcium channel, voltage-dependent, T type, alpha 1H subunit |
|
decreases expression |
EXP |
10 |
14,621,372 |
14,679,051 |
RGD:6480464 |
CTD |
| G |
Calca |
calcitonin-related polypeptide alpha |
|
multiple interactions |
ISO |
1 |
172,686,168 |
172,691,061 |
RGD:6480464 |
CTD |
| G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
|
multiple interactions |
EXP |
18 |
56,879,247 |
56,948,537 |
RGD:6480464 |
CTD |
| G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
|
multiple interactions |
EXP |
18 |
25,404,123 |
25,625,785 |
RGD:6480464 |
CTD |
| G |
Casp12 |
caspase 12 |
|
multiple interactions |
ISO |
8 |
2,082,933 |
2,110,511 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases expression |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp7 |
caspase 7 |
|
multiple interactions |
ISO |
1 |
262,689,300 |
262,721,591 |
RGD:6480464 |
CTD |
| G |
Clu |
clusterin |
|
affects expression |
ISO |
15 |
45,365,779 |
45,405,314 |
RGD:6480464 |
CTD |
| G |
Csrp3 |
cysteine and glycine-rich protein 3 (cardiac LIM protein) |
|
decreases localization |
EXP |
1 |
98,601,681 |
98,611,747 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
multiple interactions |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
decreases activity |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Cyp3a18 |
cytochrome P450, family 3, subfamily a, polypeptide 18 |
|
decreases expression |
EXP |
12 |
9,086,752 |
9,136,606 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
affects metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
decreases activity |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
affects metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
decreases activity |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
affects metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
|
decreases activity |
ISO |
12 |
17,164,384 |
17,204,589 |
RGD:6480464 |
CTD |
| G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
|
decreases expression |
EXP |
12 |
17,164,384 |
17,204,589 |
RGD:6480464 |
CTD |
| G |
Drd1 |
dopamine receptor D1 |
|
multiple interactions |
ISO |
17 |
16,655,926 |
16,658,161 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
multiple interactions |
ISO |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
ISO |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Gal |
galanin/GMAP prepropeptide |
|
affects expression |
ISO |
1 |
205,936,352 |
205,941,215 |
RGD:6480464 |
CTD |
| G |
Gap43 |
growth associated protein 43 |
|
affects expression |
ISO |
11 |
59,989,085 |
60,083,971 |
RGD:6480464 |
CTD |
| G |
Gfap |
glial fibrillary acidic protein |
|
multiple interactions |
EXP |
10 |
92,059,881 |
92,068,555 |
RGD:6480464 |
CTD |
| G |
Gfap |
glial fibrillary acidic protein |
|
multiple interactions |
EXP |
10 |
92,059,881 |
92,068,555 |
RGD:6480464 |
CTD |
| G |
Iapp |
islet amyloid polypeptide |
|
multiple interactions |
EXP |
4 |
179,855,956 |
179,860,871 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Kcna10 |
potassium voltage-gated channel, shaker-related subfamily, member 10 |
|
multiple interactions |
ISO |
2 |
202,641,065 |
202,653,140 |
RGD:6480464 |
CTD |
| G |
Kcnd3 |
potassium voltage-gated channel, Shal-related subfamily, member 3 |
|
decreases activity |
ISO |
2 |
200,709,778 |
200,924,575 |
RGD:6480464 |
CTD |
| G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
|
decreases activity |
ISO |
4 |
6,192,644 |
6,224,285 |
RGD:6480464 |
CTD |
| G |
Kcnh2 |
potassium voltage-gated channel, subfamily H (eag-related), member 2 |
|
decreases activity |
ISO |
4 |
6,192,644 |
6,224,285 |
RGD:6480464 |
CTD |
| G |
Kcnmb1 |
potassium large conductance calcium-activated channel, subfamily M, beta member 1 |
|
affects response to substance |
ISO |
10 |
18,904,902 |
18,912,604 |
RGD:6480464 |
CTD |
| G |
Lif |
leukemia inhibitory factor |
|
multiple interactions |
EXP |
14 |
84,887,856 |
84,890,630 |
RGD:6480464 |
CTD |
| G |
Mapk1 |
mitogen activated protein kinase 1 |
|
multiple interactions |
ISO |
11 |
85,968,732 |
86,030,387 |
RGD:6480464 |
CTD |
| G |
Mapk3 |
mitogen activated protein kinase 3 |
|
multiple interactions |
ISO |
1 |
185,935,044 |
185,941,245 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
EXP |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
multiple interactions |
EXP |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Myh7 |
myosin, heavy chain 7, cardiac muscle, beta |
|
multiple interactions |
ISO |
15 |
33,072,928 |
33,094,595 |
RGD:6480464 |
CTD |
| G |
Myh7 |
myosin, heavy chain 7, cardiac muscle, beta |
|
decreases expression |
ISO |
15 |
33,072,928 |
33,094,595 |
RGD:6480464 |
CTD |
| G |
Myl2 |
myosin, light chain 2, regulatory, cardiac, slow |
|
decreases expression |
ISO |
12 |
35,653,745 |
35,664,700 |
RGD:6480464 |
CTD |
| G |
Myl2 |
myosin, light chain 2, regulatory, cardiac, slow |
|
multiple interactions |
ISO |
12 |
35,653,745 |
35,664,700 |
RGD:6480464 |
CTD |
| G |
Nefl |
neurofilament, light polypeptide |
|
multiple interactions |
EXP |
15 |
47,636,303 |
47,640,176 |
RGD:6480464 |
CTD |
| G |
Nefl |
neurofilament, light polypeptide |
|
multiple interactions |
EXP |
15 |
47,636,303 |
47,640,176 |
RGD:6480464 |
CTD |
| G |
Nefm |
neurofilament, medium polypeptide |
|
multiple interactions |
EXP |
15 |
47,698,371 |
47,703,350 |
RGD:6480464 |
CTD |
| G |
Nefm |
neurofilament, medium polypeptide |
|
multiple interactions |
EXP |
15 |
47,698,371 |
47,703,350 |
RGD:6480464 |
CTD |
| G |
Nppa |
natriuretic peptide A |
|
multiple interactions |
ISO |
5 |
165,074,518 |
165,075,827 |
RGD:6480464 |
CTD |
| G |
Nppa |
natriuretic peptide A |
|
affects secretion |
ISO |
5 |
165,074,518 |
165,075,827 |
RGD:6480464 |
CTD |
| G |
Nppa |
natriuretic peptide A |
|
increases expression |
ISO |
5 |
165,074,518 |
165,075,827 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
|
multiple interactions |
ISO |
13 |
96,309,670 |
96,341,486 |
RGD:6480464 |
CTD |
| G |
Pf4 |
platelet factor 4 |
|
decreases expression |
ISO |
14 |
18,812,550 |
18,813,259 |
RGD:6480464 |
CTD |
| G |
Potef |
POTE ankyrin domain family, member F |
|
multiple interactions |
EXP |
18 |
24,420,779 |
24,422,284 |
RGD:6480464 |
CTD |
| G |
Ppbp |
pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) |
|
decreases expression |
ISO |
14 |
18,816,434 |
18,817,238 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
multiple interactions |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
increases expression |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
increases secretion |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Prl |
prolactin |
|
increases expression |
ISO |
17 |
44,699,101 |
44,709,162 |
RGD:6480464 |
CTD |
| G |
Ret |
ret proto-oncogene |
|
affects expression |
ISO |
4 |
154,448,179 |
154,491,103 |
RGD:6480464 |
CTD |
| G |
Slc22a1 |
solute carrier family 22 (organic cation transporter), member 1 |
|
multiple interactions |
ISO |
1 |
42,351,239 |
42,378,295 |
RGD:6480464 |
CTD |
| G |
Slc22a3 |
solute carrier family 22 (extraneuronal monoamine transporter), member 3 |
|
multiple interactions |
ISO |
1 |
42,690,158 |
42,781,895 |
RGD:6480464 |
CTD |
| G |
Slc22a3 |
solute carrier family 22 (extraneuronal monoamine transporter), member 3 |
|
multiple interactions |
ISO |
1 |
42,690,158 |
42,781,895 |
RGD:6480464 |
CTD |
| G |
Slc22a3 |
solute carrier family 22 (extraneuronal monoamine transporter), member 3 |
|
multiple interactions |
ISO |
1 |
42,690,158 |
42,781,895 |
RGD:6480464 |
CTD |
| G |
Slc22a5 |
solute carrier family 22 (organic cation/carnitine transporter), member 5 |
|
decreases activity |
ISO |
10 |
39,311,729 |
39,338,718 |
RGD:6480464 |
CTD |
| G |
Sod1 |
superoxide dismutase 1, soluble |
|
multiple interactions |
EXP |
11 |
29,810,766 |
29,816,342 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
EXP |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Stat3 |
signal transducer and activator of transcription 3 (acute-phase response factor) |
|
multiple interactions |
EXP |
10 |
89,821,078 |
89,872,970 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
affects expression |
ISO |
X |
12,542,496 |
12,547,094 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Trh |
thyrotropin releasing hormone |
|
multiple interactions |
ISO |
4 |
126,425,212 |
126,427,670 |
RGD:6480464 |
CTD |
| G |
Tshb |
thyroid stimulating hormone, beta |
|
multiple interactions |
ISO |
2 |
197,908,308 |
197,913,186 |
RGD:6480464 |
CTD |
| G |
Vim |
vimentin |
|
multiple interactions |
EXP |
17 |
87,847,280 |
87,855,763 |
RGD:6480464 |
CTD |
| G |
Vim |
vimentin |
|
multiple interactions |
EXP |
17 |
87,847,280 |
87,855,763 |
RGD:6480464 |
CTD |
| G |
Znrd1 |
zinc ribbon domain containing 1 |
|
multiple interactions |
ISO |
20 |
1,687,673 |
1,691,591 |
RGD:6480464 |
CTD |
Term paths to the root
| Path 1 |
CHEBI ontology |
492507 |
 |
role |
482196 |
 |
biological role |
480389 |
 |
aetiopathogenetic role |
107671 |
 |
| neurotoxin |
82086 |
 |
| ammonia |
74836 |
 |
organic amino compound |
74775 |
 |
amine |
5345 |
 |
tertiary amine |
961 |
 |
(-)-lobeline |
10 |
 |
(2E)-4-\{[3-(4-bromophenyl)-1-benzofuran-6-yl]oxy\}-N-methyl-N-prop-2-en-1-ylbut-2-en-1-amine |
0 |
 |
(6S)-6-hydroxyhyoscyamine |
0 |
 |
1-isobutoxy-2-pyrrolidino-3-(N-benzylanilino)propane |
0 |
 |
16-methoxytabersonine |
0 |
 |
17-dimethylaminolobohedleolide |
0 |
 |
2-[4-(dimethylamino)styryl]-1-methylpyridinium + |
0 |
 |
2-[4-(dimethylamino)styryl]-1-methylpyridinium iodide |
0 |
 |
3-quinuclidinol + |
0 |
 |
4-(4-dihexadecylaminostyryl)-N-methylpyridium + |
0 |
 |
6-[4-(6-bromo-1,2-benzothiazol-3-yl)phenoxy]-N-methyl-N-prop-2-en-1-ylhexan-1-amine |
0 |
 |
6-\{[3-(4-bromophenyl)-1,2-benzothiazol-6-yl]oxy\}-N-methyl-N-prop-2-en-1-ylhexan-1-amine |
0 |
 |
6-\{[3-(4-bromophenyl)-1-benzofuran-6-yl]oxy\}-N-methyl-N-prop-2-en-1-ylhexan-1-amine |
0 |
 |
8-acetoxyheterophyllisine |
0 |
 |
Disperse Blue 124 |
0 |
 |
FM 1-43 dye |
0 |
 |
FM 1-43(2+) + |
0 |
 |
FM 4-64(2+) + |
0 |
 |
LDS 751(1+) + |
0 |
 |
N(6),N(6)-dimethyladenine |
9 |
 |
N,N-diethylcyanoacetamide |
0 |
 |
N,N-dimethyl-1-(5-pyridin-3-ylfuran-2-yl)methanamine |
0 |
 |
N,N-dimethylaniline + |
2 |
 |
N,N-dimethylbutylamine |
0 |
 |
N,N-dimethylcyclohexylamine |
0 |
 |
N,N-dimethylethanolamine + |
1 |
 |
N-(trans-4'-nitro-4-stilbenyl)-N-methyl-5-aminopentanoic acid |
0 |
 |
N-methyl-1,2,3,4-tetrahydroquinoline |
0 |
 |
NK154183B |
0 |
 |
PicoGreen |
0 |
 |
SYBR Green I |
0 |
 |
aceprometazine + |
0 |
 |
almotriptan + |
14 |
 |
alverine |
1 |
 |
aminophenazone |
1 |
 |
amitriptyline |
190 |
 |
azatadine + |
1 |
 |
benzphetamine + |
2 |
 |
bepridil + |
11 |
 |
bufotenin + |
0 |
 |
butenafine + |
0 |
 |
ceratamine A |
0 |
 |
chlorpromazine + |
189 |
 |
chlorprothixene + |
4 |
 |
cinchocaine + |
3 |
 |
clomiphene + |
20 |
 |
cyproheptadine + |
5 |
 |
dicyclomine + |
0 |
 |
diethylpropion + |
0 |
 |
difenoxin + |
0 |
 |
dimethylthiambutene |
0 |
 |
diphenhydramine + |
22 |
 |
diphenoxylate + |
0 |
 |
diphenylpyraline + |
1 |
 |
dipyridamole |
85 |
 |
disopyramide + |
8 |
 |
doxylamine |
1 |
 |
eschscholtzidine |
0 |
 |
exciton(1+) + |
0 |
 |
fexofenadine |
0 |
 |
gallamine |
0 |
 |
lumefantrine |
0 |
 |
lupanine + |
0 |
 |
malachite green isothiocyanate cation + |
0 |
 |
methadone + |
40 |
 |
methotrimeprazine |
0 |
 |
nothramicin |
0 |
 |
oxybutynin + |
7 |
 |
patent blue V |
0 |
 |
promazine + |
2 |
 |
promethazine |
13 |
 |
| | |
|